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SUMMARY 
 
The normal cellular prion protein (PrPc) plays a dual role in transmissible spongiform 
encephalopathies (TSE), which is a group of lethal disease affecting humans and a variety of 
animal species. First PrPC is hypothesized to be the source of the causative agent “the prion” 
in TSE, as the pathologic missfolded scrapie isoform of the prion protein (PrPSC) catalyses its 
own conversion from the prion protein. Second, there is substantial evidence that PrPC is the 
receptor mediating neurotoxicity and disease progression in TSE. In support of this theory, 
some antiprion antibodies have been found to induce neurotoxicity, an important discovery 
that may provide a new model system to investigate the pathologic interaction between 
PrPSC and PrPC.  
In the first part of the thesis I investigated antiprion mediated toxicity in vivo. Towards this 
goal, I established two read outs based on magnetic resonance imaging (MRI) volumetry 
allowing the measurment of antiprion induced neurotoxicity in intact mice over time. In the 
beginning I worked with Manganese Enhanced MRI (MEMRI) to visualize cerebellar lesion 
induction. As this was less well suited to the measurement of the neurotoxic induction in the 
hippocampus, I additionally established a diffusion weighted imaging (DWI) scan protocol. 
Diffusion restriction can be found within an hour after the injection of high concentration of 
monovalent fragments of the neurotoxic antiprion antibody POM1. As previously found in 
cerebellar organotypic slice cultures (COCS) antiprion mediated neurotoxicity was found to 
be target and eptiopic specific. Neuronal expression of PrPC is sufficient for lesion induction 
and lesion induction is independent from cross-linking.  
Further I investigated important signalling pathways downstream of PrPC. Reactive oxygen 
species (ROS) are a known mediator of neurodegenerative disease and I could demonstrate 
that they are important in the pathologic cascade of antiprion mediated neurotoxicitiy in vivo. 
As a major source of ROS, I identified NADPH oxidase 2 (NOX2). As in bona fide prion 
infection, I could detect fodrin cleavage as a marker for calpain activation in homogenates 
from antiprion injected brain tissue. These findings are indicative that similar pathways are 
  6
activated in both pathological conditions. Further, my data shows that the NCX3 antiporter is 
a possible source of pathologic Ca2+ currents in the antiprion antibody model.  
In the second part of this thesis, I focused on the risk characterization of neurotoxic antiprion 
antibodies. Despite reports about the neurotoxic side effects of antiprion antibodies, passive 
immunotherapy with these ligands is still a therapeutic strategy under investigation in the 
treatment of TSE. Using my established MRI based quantification system and basic 
histological methods, I assessed the neurotoxic potential of the antiprion antibody ICSM18, 
which is under evaluation as a therapeutic agent for TSE in humans. Unless further 
investigations can confirm a safe therapeutic window for the use of these antibodies and 
others, my findings suggest that utmost caution is indicated.  
Here I show that Magnetic Resonance Imaging is a valuable tool in the assessment of anti 
prion mediated neurotoxicity in vivo. This technique can be used for the risk characterization 
of antiption antibodies. In addition, our work in vivo and in cerebellar slice cultures provides 
new evidence that neurotoxic antiprion antibodies model the pathologic interaction of PrPSC 
with PrPC. Thus, the established tool can be used in further studies to investigate prion-
mediated neurotoxicity, in a much shorter time frame and within biosafety level one.  
  
  7
ZUSAMMENFASSUNG 
 
Das normale zelluläre Prionprotein (PrPZ) spielt eine duale Rolle in transmissiblen 
spongiformen Enzephalopathien (TSE), eine Gruppe von lethalen Erkrankungen, welche 
Menschen und diverse Tierspezies betrifft. Erstens besteht die Hypothese das PrPZ die 
Quelle des kausativen Agens “dem Prion” in TSE ist, da die pathologische misgefaltete 
“scrapie” Isofrom des Prionproteins (PrPSC) seine eigene Konversion vom Prionprotein 
katalysiert. Zweitens, gibt es eine fundierte Evidenz, dass PrPZ der Rezeptor ist, welcher die 
Neurotoxizität weiterleitet und zur Krankheitsprogression in TSE beiträgt. Unterstützend für 
diese Theorie ist der Befund, dass Antikörper gegen das Prionprotein neurotoxisch sind; dies 
stellt eine wichtige Entdeckung dar, da es ein neues Modelsystem ermöglicht, um 
pathologische Interaktionen zwischen PrPSC and PrPZ zu untersuchen.  
Im ersten Teil meiner Thesis habe ich die Neurotoxizität vermittelt durch anti Prion Antikörper 
in vivo erforscht. Um dieses Ziel zu erreichen habe ich zwei Messsysteme basierend auf 
Volumetrie mittels des Einsatzes von Magnet Resonanz Tomographie (MRT) etabliert, 
welches das Messen von anti Prion induzierter Toxizität über die Zeit in lebenden Mäusen 
erlaubt. Um Läsionen im Kleinhirn darzustellen habe ich am Anfang mit Mangan 
unterstütztem MRT gearbeitet. Da sich herausgestellt hat, dass diese Technik weniger 
geeignet für die Messung von anti Prion Antikörper induzierter Neurotoxizität im 
Hippokampus ist, etablierte ich zusätzlich ein Bildgebungs Protokoll mittels der Verwendung 
einer Diffusions gewichteten Sequenz. Eine Diffusionsrestriktion kann innerhalb von einer 
Stunde nach Injektion von konzentrierten monovalenten Fragmenten des neurotoxischen anti 
Prion Antikörpers POM1 gefunden werden. Wie bereits in zerebellären organotypischen 
Schnittkulturen gezeigt, ist die anti Prion vermittelt Neurotoxizität Antigen und Epitop 
spezifisch. Für eine Induktion einer Läsion ist die neuronale Expression von PrPZ 
ausreichend und eine Vernetzung von PrPZ unnötig.  
Weiter habe ich Signalwege welche dem PrPZ nachgeordnet sind untersucht. Reaktive 
Sauerstoffverbindungen sind ein bekannter Mediator neurodegenerativer Erkrankungen und 
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ich konnte demonstrieren, dass jene wichtig sind in der pathologischen Kaskade der anti 
Prion Antikörper induzierten Toxizität in vivo. Als eine Hauptquelle der reaktiven 
Sauerstoffverbindungen habe ich die NADPH Oxidase 2 identifiziert. Wie bei einer echten 
Prioneninfektion konnte ich zudem ein typisches Verdau Muster des Fodrin Proteins als 
Marker für eine Calpain Aktivierung im Homogenat von anti Prion Antikörper injeziertem 
Gehirngewebe finden. Diese Befunde sind hinweisend dafür, dass in beiden pathologischen 
Bedingungen ähnliche Signalwege aktiviert werden. Zusätzlich zeigen meine Daten, dass 
der NCX3 Antiporter eine mögliche Quelle für pathologische Ca2+ Ströme im anti Prion 
Antikörper Modell ist. 
Im zweiten Teil meiner Thesis habe ich mich auf die Risikocharakterisierung von anti Prion 
Antikörper fokusiert. Trotz den Berichten bezüglich der neurotoxischen Nebenwirkungen 
dieser Antikörper, ist die passive Immunotherapie immer noch eine häufig getestete 
Behandlungsstrategie in TSE. Mittels des MRI basierten Quantifikationssystems und 
Histologie habe ich das neurotoxische Potential des anti Prion Antikörpers ICSM18 
untersucht, welcher in Evaluation als ein Therapeutikum in TSE beim Menschen steht. Meine 
Befunde mahnen zur Vorsicht in Bezug auf den therapeutischen Gebrauch dieses und 
anderer Antikörper.  
Hier zeige ich, dass MRT ein wertvolles Werkzeug für die Bewertung von anti Prion 
Antikörper vermittelte Neurotoxizität in vivo darstellt. Diese Techik kann für die 
Risikobewertung von anti Prion Antikörper verwendet werden. Zweitens liefern unsere 
Arbeiten in vivo und in zerebellären organotypischen Schnitt Kulturen eine Evidenz, dass 
neurotoxische anti Prion Antikörper pathologische Interaktionen von PrPSC mit PrPC imitieren. 
Das hier etablierte in vivo Model kann deshalb auch für weitere Studien zur Untersuchung 
der Prion vermittelte Neurotoxizität verwendet werden. Dies bietet den Vorteil, dass jene in 
einer viel kürzeren Zeitperiode und unter einem Biosicherheitlevel eins untersucht werden 
können.  
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ABBREVIATIONS 
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INTRODUCTION 
 
From the disease to the dual pathogenic role of the cellular prion protein 
Transmissible spongiform encephalopathies and the protein only hypothesis 
Transmissible spongiform encepahlopathies (TSE) diseases are untreatable, fatal 
neurodegenerative diseases with an unsolved pathological mechanism (Aguzzi and Calella, 
2009). The first clinical manifestation of a TSE is known since 1738 (Figure 1A) in sheep and 
named scarpie (Aguzzi and Calella, 2009). Creutzfeldt (1920) and Jakob (1921) described 
the disease first in humans and gave the eponym for the disease in humans (Aguzzi et al., 
2008). The majority (85%) of TSE cases in humans are the sporadic, and inherited (10-20%), 
associated with autosomal dominant PRNP gene alterations, forms of Creutzfeld-Jakob 
Disease (CJD) (Aguzzi and Calella, 2009).  
Per definition, TSE are transmissible, which was first recognized for scrapie in 1946, when 
the contamination of a vaccine led to the infection of 1’500 sheeps (Aguzzi and Calella, 2009; 
Gordon, 1946). In man the infectious nature was initially recognized by Gajdusek, who 
discovered that the practice of ritual cannibalism led to the disease known as Kuru in 150 
villages in New Guinea (Gajdusek and Zigas, 1957). The description of the new variant of 
CJD (Chazot et al., 1996; Will et al., 1996) generated global interest in the infectious nature 
of TSE. Subsequently, a global food panic (Aguzzi and Calella, 2009) was triggered by the 
announcement that the most likely aetiology of this form was the consumption of meat from 
cattle infected by the epidemic spread of Bovine Spongiform Encephalopathy (BSE) 
(Anderson et al., 1996).  
The definitive diagnosis in TSE is to date based on neuropathological examination (WHO, 
1998). The classical hallmark of the disease (Figure 1B) is spongiform change, neuronal 
loss and gliosis (Budka, 2003). On routine staining with hematoxylin & eosin (H&E), compact 
Kuru-type plaques are seen in some cases of TSE (Budka, 2003). These exhibit a 
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characteristic apple-green birefringence when stained with Congo red and observed under 
polarized light, a characteristic feature of amyloid proteins (Aguzzi and O'Connor, 2010). 
The clinical presentation of the encephalopathie differs between and within entities. Based 
on World Health Organisation (WHO) criteria, patients are scored as probable or possible 
cases (WHO, 1998). Sporadic CJD (sCJD) cases typically present with rapidly progressive 
dementia and at least two of the following four clinical features: myoclonus, visual or 
cerebellar disturbances, pyramidal or extrapyramidal dysfunction, and akinetic mutism 
(WHO, 1998).  
 
Figure 1: A pathologic protein isoform encoded by PRNP induces transmissible spongiform 
encephalopathy (TSE) in humans and animals 
(A) The time bar illustrates the years of the first description of TSE in humans and animals (upper) and 
important discoveries leading to the identification of the infective agent (lower). CJD: Creutzfeld Jakob 
Disease, GSS: Gerstmann-Sträussler-Scheinker disease, FFI: Fatal Familial Insomnia, BSE: Bovine 
Spongiform Encephalopathie, vCJD: new variant CJD, VPSPr: variable Protease Sensitive 
Prionopathy. (B) Hematoxylin & Eosin (H&E)-stained micrograph of a cerebellar section from a patient 
who died from sCJD (left), depicts the classical neuropathological hallmarks of TSE: spongiform 
change (star), nerve cell (neuronal) loss and reactive gliosis (arrow). These changes are not found 
upon histological examination of unaffected patients (left). Molecular layer: ML; Purkinje cell layer: 
PCL; Granular cell layer: GCL. (Source of micrograph: National Reference Center for Prion Diseases, 
Switzerland)  
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The nature of the infectious agent was a scientific mystery for decades (Figure 1A). The 
„scrapie agent“possessed unusual properties such as resistance to high temperature (Stamp 
et al., 1959), fixation with formalin (Pattison, 1965) and ultra-violet irradiation (Alper et al., 
1967). From these experiments, it was concluded that the agent replicates without nucleic 
acid (Alper et al., 1967). In 1967, Griffith proposed three possible mechanisms of how a 
protein could be the self-replicating agent in TSE (Griffith, 1967). The protein only 
hypothesis (Prusiner, 1991; Weissmann, 1991) was associated with the introduction of the 
term prion by Prusiner, denoting a small proteinacious infectious particle, which is today the 
common term for the infective agent in TSE (Prusiner, 1982). Only a few months later, his 
group presented data about a purified preparation of prions, which was found to consist of a 
single major protein (Bolton et al., 1982; Prusiner et al., 1983). Additionally, Prusiner 
discovered that this protein aggregated into amyloid-like birefrigent rods or fibrils, and thus 
concluded that the plaques found in TSE likely consist of prions (Prusiner et al., 1983). The 
gene known as Prnp encodes this pathologic protein and the normal cellular prion protein 
(Basler et al., 1986). PrPC refers to the normal cellular isoform of the prion protein, which is 
protease sensitive and soluble in nondenaturing detergents, whereas the scarpie isoform of 
the prion protein PrPSC is the disease-specific protein, which is insoluble in detergents 
(Aguzzi and Calella, 2009). Typically, this pathologic isoform has a protease-resistant core of 
a 33 to 35 kDa, designated as PrPRes and used to detect prions in research or diagnostic 
tests. On immunohistochemical analysis of tissue from TSE infected animals and humans, 
aggregates of PrPRes are found in a synaptic, patchy/perivacuolar, or plaque like pattern 
(Budka, 2003). Possible posttranslational modifications convert PrPC in PrPSC (Basler et al., 
1986). There is evidence that certain “co-factors” like lipids or RNA increase the infectivity of 
PrPSC (Deleault et al., 2007; Supattapone, 2010; Wang et al., 2010).  
With the hallmark of the misfolding and aggregation of proteins into fibrils, TSE belong to a 
family of degenerative diseases, termed as proteinopathies or proteopathies. The best 
recognized member of this group is Alzheimer disease, associated with the pathologic 
accumulation of amyloid β (Aβ) and tau protein. Interestingly, there is a growing body of 
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knowledge that proteinopathies share additional features than just the aggregation of 
misfolded proteins (Aguzzi and Rajendran, 2009; Eisenberg and Jucker, 2012; Jucker and 
Walker, 2011). 
 
The cellular prion protein 
The PRNP gene was assigned to the human chromosome 20 and Prnp to the corresponding 
mouse chromosome 2 (Sparkes et al., 1986). The open reading frame (ORF) is contained 
within a single exon and codes for PrPC, ubiquitously expressed, particularly in the nervous 
system by neurons and glial cells (Aguzzi and Calella, 2009). PrPC is a 
glycosylphosphatidylinositol (GPI) anchored cell surface protein (Stahl et al., 1987) 
consisting of 209 Amino Acids (Aguzzi and Calella, 2009). Structurally, the protein (Figure 2) 
can be segmented into a N-terminal flexible tail (FT, amino acids 23-125) and a C-terminal 
globular domain (GD, amino acids 124-230) (Riek et al., 1997). Both segments can be 
further subdivided into structural or functional domains. The FT consists of two charged-
clusters (CC1 and CC2), five octapeptide repeats (OR) and the hydrophobic core (HC) 
(Aguzzi et al., 2008). The structurally better defined GD is composed of two beta sheets (3% 
of the structure) and three alpha helices (Hornemann et al., 1997; Riek et al., 1997). In 
contrast, PrPSC has been found to have a much higher beta sheet content of 43% (Pan et al., 
1993).  
 
Figure 2: Structural and functional domains of the cellular prion protein (PrPC) 
The two major structural components of PrPC are the unstructured flexible tail (FT) and the C-terminal 
globular domain (GD). At the C-terminal, the protein is linked with a glycosylphosphatidylinositol (GPI) 
anchor with the cell membrane. CC1: charged amino acid cluster 1; OR: octa repeat, CC2: charged 
amino acid cluster 2; H1-H3: three α-helices (red boxes); S-S: disulfide bond; red forks: potential sides 
of N-linked glycosylation. Modified from (Aguzzi et al., 2008). 
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Interestingly, no severe phenotype has been found in PrPC deficient mice (Prnp°/°) (Büeler et 
al., 1992). This observation was unexpected as the high conservation of central domains of 
PrPC between species, was indicative for an essential function of the protein (Aguzzi et al., 
2008). Later PrPC expression was shown to be essential for myelin maintenance (Bremer et 
al., 2010) and to influence many cellular processes, including neuronal survival, neurite 
outgrowth and synapse formation (Aguzzi et al., 2008). However, the function of PrPC is 
controversial, as some findings are based on genetic confounders (Nuvolone et al., 2013).  
 
The pathologic agent is recruited from PrPC  
The central role of PrPC in prion pathogenesis is illustrated by the striking phenotype of 
Prnp°/° mice with their resistance to prion infection (Büeler et al., 1992). Today the theory 
that prions are self-replicating proteins, which catalyse their own conversion from PrPC, is 
widely accepted (Aguzzi and Calella, 2009). Thereby, not the monomeric form but oligomeric 
species of approximately 20 molecules show the most effective infectivity (Silveira et al., 
2005). This finding speaks in favour of the seeded nucleation theory, one of the hypotheses 
explaining the recruitment of prions from normal PrPC (Jarrett and Lansbury, 1993). This 
model makes the assumption that PrPC and the pathological beta sheet rich isoform are in a 
thermodynamic equilibrium and shifted in the non-diseased state towards PrPC. Highly 
ordered seeds of monomeric PrPSC incorporate other monomers, aggregate or fragment into 
new seeds and thereby propagate (Aguzzi and Calella, 2009).  
 
Evidence that PrPC acts as a neurotoxic mediator in TSE 
Neuronal cell loss is one of the three central neuropathological hallmarks of TSE. There is a 
growing body of evidence that the translated product of the Prnp gene is not only the main 
content of prions, but also that its normal isoform PrPC anchored to the membrane is the 
receptor mediating neurotoxicity. Brain tissue devoid of PrPC is not damaged by 
accumulating PrPSC, even in close proximitry to the tissue graft with established prion 
infection (Brandner et al., 1996). Additionally, depletion of endogenous PrPC expression 
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during prion infection resulted in preserved neuronal cell loss and spongiosis (Mallucci et al., 
2003). Remarkably, prion infection in mice expressing only an anchorless Prion Protein fails 
to induce any clinical manifestations despite the deposition of PrPRes (Chesebro et al., 2005). 
Different models of how PrPC could act within the neurotoxic cascade have been 
promulgated: (1) PrPSC could lead to a clustering and/or conformational change of PrPC 
(Figure 3) on the cell surface and (2) PrPC could mediate lysosomal uptake and/or clustering. 
This could lead to aggregation of misfolded protein within the endoplasmatic reticulum (ER), 
which triggers the Unfolded Protein Response (Halliday and Mallucci, 2014).  
 
Figure 3: Bonafide PrPSC infection hypothetically induces neurotoxicity through interaction 
with PrPC  
(A) Illustration of the normal PrPC. Depicted is the Flexible Tail (FT), the Octapeptide Repeat 
(OR) and the Globular domain (GD). (B) Interaction of monomeric or oligomeric PrPSC with 
PrPC triggers neurotoxicity. Neurotoxicity is possibly induced through a conformation 
alteration (illustrated by a change in the conformation) of the FT.  
 
In a broader hypothesis, PrPC is believed to be a receptor for amyloids in general. This 
concept mainly developed from the identification of PrPC (epitope 95-105) as an Aβ-oligomer 
receptor mediating synaptic dysfunction (Lauren et al., 2009). Although the interaction of Aβ-
oligomer with PrPC was later confirmed (Balducci et al., 2010), the blockage of Aβ-oligomer 
triggered synaptic plasticity impairment upon Prnp ablation is considered controversial 
(Aguzzi and Calella, 2009; Kessels et al., 2010).   
Spontaneous neurodegeneration has been observed in mice expressing mutated CC2 
ablated PrP in combination with a partial deletion of the HC: the mutants PrP∆32-121, PrP∆32-134, 
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PrP∆105-125 and PrP∆94-134 (Baumann et al., 2007; Li et al., 2007; Shmerling et al., 1998). A 
similar phenotype is seen in mice ectopically overexpressing Doppel in the absence of 
normal PrPC (Mo et al., 2001; Moore et al., 1999; Rossi et al., 2001; Sakaguchi et al., 1996). 
Importantly, the co-expression of normal PrPC in combination with the deletion mutants or 
Doppel is protective against these pathological effects (Anderson et al., 2004; Atarashi et al., 
2003; Nishida et al., 1999; Shmerling et al., 1998), which argues for a neuroprotective activity 
of the full-length prion protein (Beland and Roucou, 2012).  
 
Cellular signalling through PrPC  
PrPC as a GPI anchored receptor could possibly influence intracellular signalling transduction 
pathways by two mechanisms: either by interaction with a transmembrane adapter or a cell-
surface complex or by ligand induced PrPC mislocalization into a transmembrane or cytosolic 
form (Aguzzi et al., 2008).  
To identify the PrPC interaction partners, a huge effort has been made, and several 
membrane proteins (receptors, enzymes, Caveolin-1, Na-K-ATPase, and a potassium 
channel), cytoplasmic proteins (components of the cytoskeleton, heat-shock proteins, and 
adaptor proteins involved in signalling), and even the nuclear protein CBP70 were identified 
(Aguzzi et al., 2008). However, many of these studies, which were based on yeast-two 
hybrid, co-immunoprecipitations, and cross-linking experiments, are limited due to technical 
issues (Aguzzi and Calella, 2009). To overcome some of these concerns, additional 
transgenic mice expressing a functionally tagged PrPC were used and several proteins 
associated with axomyelinic maintenance were identified (Rutishauser et al., 2009).  
Within the ER, PrPC can adopt at least two transmembrane topologies, CtmPrP and NtmPrP, 
which have their carboxyl or amino terminus in the ER lumen, respectively (Aguzzi and 
Calella, 2009). Neurodegenerative changes have been reported for mice expressing the 
CtmPrP transmembrane form (Hegde et al., 1998) and for the accumulation of the prion 
protein in the cytosol (Ma et al., 2002), which support the role of aberrant PrPC topology in 
the neurotoxic cascade.  
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Antiprion antibodies 
The first antiserum against prion protein was produced in 1984 (Bendheim et al., 1984); 
however, the generation of high affinity antiprion antibodies was complicated by host 
tolerance to endogenous PrPC, which is nonpermissive to generate high-affinity antiprion cell-
clones (Polymenidou et al., 2004).  The first successful monoclonal antibody 3F4, was 
derived from a mouse immunized with hamster PrPres, which binds to human and hamster 
but not to mice PrP (Kascsak et al., 1987). The breakthrough in generating larger panels of 
antibodies against different epitopes was achieved by immunization of Prnp°/° mice 
(Williamson et al., 1996). Specifically, a set of 19-specific antibodies, including the antiprion 
antibody D13 (epitope 95-105; Figure 4A), was produced with antibody-phage technology or 
liposome preparation (Williamson et al., 1998).  
 
 
Figure 4: Illustration of epitopes of antiprion antibody binding sites  
(A) Antibody binding sites on PrP (epitope 23-230). POM2, 11 and 12 bind epitopes of the OR (bright 
blue). Epitopes of CC2 are recognized by POM3 and D13 (pink) POM6-9, 13, 15 and 17 and ICSM-18 
bind helix α1 and compete with POM1 (Polymenidou et al., 2004). POM6 and POM7 (light orange) 
show additional binding sites at helix α2 (dark orange), whereas POM5 recognizes a unique epitope at 
the β2-α2 transition (green). The GD image was generated using the RSCB Protein Data Bank (PDB) 
structure 2L1H. (B) Surface stereoview of human PrP(121-230). Yellow and cyan: POM1 and ICSM18 
interfaces, respectively (PDB accession codes: 4DGI and 2W9E). Magenta: overlap between the 
POM1 and ICSM18 interfaces. Blue ribbon: polypeptide backbone. Interfaces are delineated by 
residues with ≤5 Å distance in the complexes comprising human PrP (epitope 121-230) and the 
respective F(ab) fragments. Structural images were prepared with the program PyMOL 
(www.pymol.org)  
 
 
Based on the immunization of Prnp°/° with recombinant human PrP (residues 91-231), folded 
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either into α or β conformation, ICSM antibodies have been generated primarily to study 
differences in expression of PrPC (Beringue et al., 2003). These sets mostly exclude epitope 
specificity with the FT. Accordingly POM monoclonals (Figure 4A) were generated by 
immunization of Prnp°/° with full length recombinant murine PrP (rmPrP23-230) (Polymenidou et 
al., 2008). Crystallographic studies and nuclear magnetic resonance spectroscopy showed 
that 10 amino acids overlap in the binding epitope of POM1 with ICSM18 (Figure 4B). 
 
Antiprion mediated neurotoxicity 
Antiprion antibodies have been used to demonstrate signal transduction through PrPC 
(Mouillet-Richard et al., 2000) by the use of the neuronal differentiation model 1C11. In 2004 
Solforosi et al. induced neuronal apoptosis upon intrahippocampal and intracerebellar 
injection of antiprion antibodies in vivo. While two of their antibodies D13 and P, both 
recognizing epitopes within the 95 to 105 region of the prion protein, showed a pathologic 
effect, D18, binding within 133 to 157, was not toxic at the same dose. The toxic induction 
was a specific effect upon PrPC binding, since it could be blocked upon incubation with 
rmPrP90-230 and it was not seen upon injection into Prnp°/° mice. The neuronal damage was 
primarily characterized as pyknotic nuclei by conventional histology. Transferase mediated 
deoxyuridine triphosphate nick end labelling (TUNEL) revealed apoptotic neuronal cell death. 
Immunohistochemistry excluded complement activation and FC mediated toxicity. However, 
the injection of monovalent fragment antigen (F(ab)1) of D13 and P did not cause anti-prion 
mediated toxicity. From this observation it was concluded that the toxicity is cross-link 
mediated. This neurotoxic effect was introduced as a possibile model for the negative prion 
interaction with PrPC and as a justification to avoid the use of these antibodies for therapeutic 
intervention (Solforosi et al., 2004). The toxic effect of anti-prion antibodies was later 
confirmed (Lefebvre-Roque et al., 2007) by a model designed to treat prion-infected mice 
after the chronic administration of antiprion antibodies. However, subsequently there was a 
report that questioned the neurotoxic effect of D13 (Klöhn et al., 2012). 
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Magnetic resonance imaging in TSE 
MRI as a non invasive tool in research and diagnosis  
Magnetic resonance imaging (MRI) is an extraordinary technique that facilitates non-invasive 
in vivo imaging for diagnostic and research purposes. Due to the high contrast soft tissue 
structures on MRI, it is possible to examine anatomical structures and biochemical processes 
inside the body (Meier D. et al., 2012). The technique is based on the discovery in 1946 by 
Bloch and Purcell (Bloch et al., 1946a, b; Purcell E. M. et al., 1945) “that certain nuclei 
absorb energy in the electromagnetic spectrum when placed in a magnetic field, which is re-
emitted when the nuclei return to their original energy state” (Geva, 2006), resulting in the 
birth of the field of Nuclear Magnetic Resonance (NMR). “With NMR the structures of 
molecules can be identified to facilitate the analysis of solutions and to follow chemical 
reactions in physics and chemistry” (Meier D. et al., 2012). In 1974, Lauterbur and Mansfield 
advanced the development of the technique (Lauterbur, 1973) with the spatial localization of 
the NMR signal, which provided the foundation of the MRI technique (Geva, 2006). Finally, 
the use of Fourier transformation, introduced by Ernst 1975, allowed rapid image 
reconstruction from NMR signals (Geva, 2006) and created the basis for the implementation 
of MRI as a routine clinical method.  
Meier and Schild explain that MRI is mainly based on the magnetic properties of hydrogen 
(1H) nuclei. 1H possesses an inherent angular momentum or spin like other atomic nuclei with 
an odd number of protons or neutrons. As 1H is a positively charged particle, this spin causes 
a magnetic moment. If a tissue or a body containing large number of 1H is placed into a static 
magnetic field, net magnetization results parallel to this external field. This longitudinal 
magnetization (Figure 5A) is the sum of individual 1H magnetic moments. Energy can then 
be transferred to this system by irradiation with a Radio Frequency (RF) Pulse in resonance 
to the 1H nuclei. Some of the magnetic moments consequently assume a new position in the 
external magnetic field, what leads to a flip of the sum magnetic moment. Illustrated in a 3D 
coordinate system as a flip of the longitudinal magnetization vector into the xy-plane (Figure 
5A), this new transversal magnetization induces an electromagnetic signal into an antenna 
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recorded in an MRI experiment known as the free induction decay (FID). After the RF pulse 
is switched off, the sum of the magnetic moments are again aligned with the external static 
magnetic field. In other words, longitudinal magnetization recovers and the transversal 
magnetization decays. The time it takes for longitudinal relaxation is known as the 
longitudinal or spin-lattice relaxation time T1 and the signal decay is described with the 
transverse or spin-spin relaxation time T2* .In an MRI experiment, the RF pulse is applied 
several times. The time between two pulses is called the time of repetition (TR). Different 
tissues have a characteristic T1, thus after a short TR their longitudinal magnetization differs 
(Figure 5B). It is impossible to measure the FID directly when the RF pulse is switched on. 
Thus, an echo of the signal has to be generated at the time of echo (TE). This echo is 
induced in a spin-echo-sequence by applying a second 180° RF pulse (Figure 5C) and in a 
gradient-echo-sequence by inverting magnetic field gradients. By applying multiple echo 
pulses the signal decays slower than T2* with the time T2 (Figure 5C) (Meier D. et al., 2012; 
Schild, 1990).  
 
Figure 5: In MRI the transverse magnetization is 
measured 
(A) Illustration of the net longitudinal magnetic 
moment (red vector), which stands parallel to the 
external magnetic field. A radio frequency (RF) 
pulse switches the net magnetic moment into the x-y 
plane resulting in a transverse magnetization 
(second red vector, right side). The transverse 
magnetization can induce a measurable signal in a transmitter coil, the Free Induction Decay (FID). 
(B) The time between two RF pulses is called time of repetition (TR). The recovery time of the 
longitudinal magnetization, known as T1 time, differs between tissues; illustrated here as tissue a 
(blue) and b (green). Depending on TR, a difference in the longitudinal and transverse magnetization 
between theses tissues result over time. (C) After the RF pulse is switched off, the protons diphase 
and the transverse magnetization disappear. A 180° signal can refocus the protons resulting in an 
echo signal. The time of echo (TE) refers to the time from the initial RF pulse until the echo appears. 
(D) Without echo pulses, the FID would decay with the time T2*. The 180° pulses are resulting in a 
prolongation of the signal with the time T2. Illustration in the style of MRI made easy, Prof. H. Schild 
(Schild, 1990).  
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Meier and Schild further explain, that in contrast to other imaging modalities, MRI allows the 
assessment of multi-dimensional information in a single scanning session. Basically, by 
altering TR or TE, either the proton density or the relaxation time T1 or T2 can be displayed, 
which are characteristic for different tissues (Figure 6A). A long TR and a short TE result in 
proton-weighted images (Figure 6B). In contrast, when a long TE is chosen, a strong T2 
contrast results (Figure 6C). To record differences in signal intensity based on characteristic 
T1 times, sequences with a short TR and TE are used (Figure 6D) (Meier D. et al., 2012; 
Schild, 1990).  
 
 
Figure 6: Image contrast depends on tissue characteristics and on the selection of TE and TR 
(A) Illustration of the longitudinal and the transversal magnetization in one graph. TR: Time of 
Repetition, TE: Time of Echo. (B) Tissue a (blue line) has a short T1 time, resulting in a fast recovery 
of the longitudinal magnetization and a short T2 time, resulting in fast decay of the transverse 
magnetization. In contrast, tissue b (red line) has a long T1 and T2 time. For an image determined by 
the proton density, the tissue a long TR and a short TE is selected. (C) A T2 weighted image has a 
long TR and a short TE. (D) If TR and TE are chosen short a T1 weighted image results. Illustration in 
the style of MRI made easy, Prof. H. Schild (Schild, 1990). 
 
Important qualitative parameters of a MRI sequence are the signal to noise ratio (SNR), 
spatial resolution, the contrast to noise ratio and scanning time (Weishaupt et al., 2009). All 
these parameters are interconnected and influenced by each other (Figure 7A). The 
resolution is determined by the signal from a volume represented by a pixel on the MRI 
image. This volume is called a voxel and is determined by the size of its edges (Figure 7B). 
The smaller the voxel size, the higher the spatial resolution. In contrast, the voxel size is 
directly proportional to the SNR (Figure 7C). Thus, a large voxel results in good a SNR, but 
reduced spatial resolution. This can be compensated with a longer scan time. For example, 
optimization can be achieved by increasing the number of excitation (NEX), known as signal 
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averaging. The contrast to noise depends on the difference in the signal between two tissues 
and is indirectly proportional to the noise (Figure 7D).  
 
Figure 7: The signal to noise ratio is indirectly proportional to the spatial resolution 
(A) Triangle illustrating the most important quality parameters in MRI: Scan time, spatial resolution, 
signal to noise and contrast to noise ratios. (B) A Pixel on a 2D MRI image represents the signal 
recorded from a 3D voxel measured in the object. The smaller the size of a voxel is chosen the higher 
the spatial resolution. (C) The signal to noise ratio is directly proportional to voxel volume and the 
square root of the scan time. The scan time depends on the number of voxels measured in the xy-
plane, the number of excitations and the receiver bandwidth. (D) The contrast to noise ratio depends 
mainly on the difference in signal intensity between two tissues and is indirectly proportional to the 
standard deviation of noise.  
 
DWI and FLAIR imaging as standard sequences in the diagnosis of CJD 
In a multicentre study, Zerr et al. demonstrated the important role of MRI in the pre-mortem 
diagnosis of sCJD. Two sequences, fluid-attenuated inversion recovery (FLAIR) and 
diffusion-weight imaging (DWI) detected hyperintensities in basal ganglia and other cortical 
regions. DWI demonstrated a higher sensitivity over FLAIR and these signal abnormalities 
were rarely found in other proteinopathies like Alzheimer. Based on this MRI-CJD consortium 
the specified hyperintensities in FLAIR or DWI got included into the clinical pre-mortem 
diagnosis criteria for sCJD (Zerr et al., 2009). MRI has the additional potential to distinguish 
sCJD subtypes (Meissner et al., 2009) and DWI can detect changes as early as 3 weeks 
after the onset of symptoms (Shiga et al., 2004).  
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DWI measures the Brownian motion of molecules and thereby water diffusion properties 
across tissues (Meier D. et al., 2012). This sequence can detect stroke at an early phase, as 
diffusion becomes restricted very rapidly in ischemic brain tissue (Albers, 1998). The 
pathological correlate is known as cytotoxic edema, referring to the increase in intracellular 
water content due to an impaired function of the sodium pump (Albers, 1998). In contrast, the 
pathological substrate for the diffusion restriction in CJD remains unclear (Letourneau-
Guillon et al., 2012). Mainly spongiform changes and altered molecular motion of water are 
proposed (Macfarlane et al., 2007).  The initial hyperintensity disappears in the later stages 
of the disease (Matoba et al., 2001; Ukisu et al., 2005). Despite the frequent use of MRI in 
clinical diagnosis of CJD, the technique is infrequently applied to animal research in prion 
dissease, most likely due to biosafety issues.  
 
Aims 
After the detection of several TSE affecting animals and humans, decades of research have 
uncovered a dual pathological role of the prion protein. Neurodegeneration is a 
neuropathological hallmark of prion disease, but unlike the characteristic spongiform change, 
it is also found in other neurodegenerative diseases associated with amyloid formation of 
pathologically confirmed proteins (proteinopathies). The induction of acute neurotoxicity by 
antiprion antibodies represents a model to assess prion-mediated neurotoxicity. Biosafety 
issues do not affect this model system, which is an advantage for the application of a broader 
spectrum of techniques. In her PhD thesis, Tiziana Sonati substantially expanded our 
knowledge about antiprion mediated toxicity using cerebellar slice cultures (data will be 
summarized in subchapter: Results from modelling PrPC mediated neurotoxicity ex vivo).  
 
Aim 1: In vivo antiprion mediated toxicity has been mainly assessed by classical histology. 
The aim of part I of this thesis is to assess antiprion mediated neurotoxicity in living animals 
with MRI. I will first describe the establishment of the imaging protocol, then I will present 
central findings from the ex vivo system that were verified in vivo and lastly, I will present 
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data uncovering NCX3 as a potential resource of rapid calcium influx upon administration of 
neurotoxic antiprion antibodies.  
 
Aim 2: Antiprion antibodies represent one of the most promising therapeutic compounds in 
prion disease. However, reports about their neurotoxic potential underscore the need for 
caution. In recent years conflicting data have been reported about the neurotoxic potential of 
antiprion antibodies. The aim of the part II of this thesis is to evaluate the conflicting data and 
to address the question of the clinical relevance of the described toxicity.  
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PART I 
 
Introduction 
Results from modelling PrPC mediated neurotoxicity ex vivo  
Cerebellar organotypic slice cultures (COCS) have found to be a relevant tool in the 
investigation of various prion strains ex vivo (Falsig et al., 2008).  During her PhD thesis, Dr. 
T. Sonati investigated antiprion mediated neurotoxicity using organotypic slice cultures in 
order to model pathologic PrPSC interactions with PrPC (Figure 8A). Based on this extensive 
research, antiprion mediated toxicity was found to be gene dosage dependent and the 
degree of toxicity modulated by the dose and duration of antibody treatment. The induced 
toxicity was found to be epitope specific, as FT ligands do not mediate these effects. In 
addition, neuronal PrP expression was sufficient for the induction of neurodegeneration. 
Several tests with antibody derivatives (monovalent F(ab)1, divalent F(ab)2 fragments and 
single chain variable fragment (ScFv) minibodies) demonstrated that it is unlikely that 
crosslinking of PrP is the cause of neurotoxic induction. Antibody mediated toxicity was 
shown to be caspase independent and ultrastructural analysis revealed non-necrotic but 
atypical apoptotic cell death. 
Cerebellar slices from mice lacking a large part of the flexible tail including the OR, the PrPΔ
32-93 deletion mutant, were found to be resistant to the induction of antiprion mediated toxicity 
(Figure 8B).  
In addition, antiprion antibodies binding to the FT were found to be non-toxic and protective 
upon the induction of antiprion mediated neurodegeneration. Accordingly, the conclusion was 
drawn that the FT is the effector domain of prion toxicity. In contrast cerebellar slice cultures 
from mice expressing a PrP construct, cultures depleted of CC2 were susceptible to the 
induction of PrPC mediated neurotoxicity. Pharmacological inhibition studies uncovered the 
major contribution of reactive oxygen species (ROS) and calpains in the neurotoxic cascade 
downstream of PrPC. A massive increase of intracellular Calcium ion (Ca2+) was proposed, 
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but the source was not identifed. 
Based on the observation that the synthetic PrP fragment 106-126 induces neurotoxicity in 
cultured cells, a similar model system had been proposed earlier (Forloni et al., 1993). 
However, these experiments were later challenged (Kunz et al., 1999)  and the induction of 
neurotoxicity was not seen upon administration of these fragments into COCS (Sonati, 
2013a). 
 
Figure 8: The FT 
hypothetically mediates the 
toxicity of antiprion antibodies 
(A) Ligands to the GD 
hypothetically model the 
neurotoxic induction found in 
bona fide prion induction. Antiprion antibodies binding the globular domain, like POM1, induce 
neurotoxicity mediated by the FT of PrPC. Downstream of the cellular prion proteins, reactive oxygen 
species (ROS) and calpains mainly contribute to the cell damage. (B) Cerebellar slice cultures 
expressing an OR depleted form of PrPC do not show antibody mediated neurotoxicity.  
 
Oxidative stress is a mediator of prion disease 
ROS, the radical or non-radical derivatives of oxygen play a role in molecular damage 
(Fatokun et al., 2008). ROS are spontaneously generated in the inner mitochondrial 
membrane, through the activity of the electron transport chain in the ER and enzymatically by 
nicotinamide adenine dinucleotide phosphate (NADPH) oxidases (NOX) or xanthine 
oxidases like the Ca2+ dependent nitric oxide synthase (NOS), which produce the free radical 
nitric oxide (Fatokun et al., 2008). Oxidative stress, which refers to excessive ROS levels, is 
an important mediator of neuronal degeneration in proteinopathies (Fatokun et al., 2008). 
In TSE signs of oxidative stress have been demonstrated in the tissue of patients affected by 
CJD and in prion-inoculated mice (Choi et al., 1998; Guentchev et al., 2000; Ju et al., 1998). 
Additionally, oxidative stress has been described to be an early primary pathogenic effect in 
TSE (Brazier et al., 2006; Yun et al., 2006), providing evidence that oxidative stress, rather 
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than an unspecific phenomenon, is potentially a causative factor in the pathogenesis of prion 
disease. 
 
Calpains are activated in TSE 
Calpains are tightly regulated by Ca2+ cytoplasmatic cysteine protease, which can be divided 
into two species, Calpain-I (μ-calpain) and Calpain-II (m-calpain) (Suzuki, 2004). The above 
enzymes can be activated by either micromoles per litre or millimoles per litre, respectively 
(Suzuki, 2004). Calpains cleave only a restricted set of proteins, as N-methyl-D-aspartate 
(NMDA) receptor and α-spectrin (α-fodrin), participate in different signalling pathways (e.g. 
epithelial growth factor), in cellular transformation and tumorigenesis and mediate cell death 
(Croall and Ersfeld, 2007). In contrast to caspase 3, calpains are activated in various necrotic 
and apoptotic conditions (Wang, 2000).  
Alzheimer brains show an increased level of activated calpains (Taniguchi et al., 2001). The 
involvement of calpains in TSE has been demonstrated in prion inoculated cerebellar slice 
cultures (Falsig et al., 2012).  
 
Ca2+ homeostasis is altered in TSE 
Calcium (Ca2+) regulation systems are impaired in neurodegenerative disorders, leading to 
synaptic dysfunction, impaired plasticity and neuronal degeneration (Mattson, 2007). Ca2+ 
mediates neurotoxicity possibly by three different interactive cascades: first, through the 
activation of caspases; secondly, by the induction of oxidative stress; and thirdly, through the 
activation of pro-apoptotic enzymes (Mattson, 2007). 
Calcium homeostasis has shown to be altered in TSE and is possibly regulated by the 
physiological aspects of PrPC (Figure 9) (Sorgato and Bertoli, 2009). The demonstration of 
calpain activation in prion inoculated and in antiprion antibody treated cerebellar slice 
cultures indicates that increased calcium influx is an upstream event in TSE (Falsig et al., 
2012). Additionally, there is evidence that oxidative stress renders neurons vulnerable to 
excitotoxicity, based on the overactivation of glutamate receptors (Mattson, 2007). Chronic 
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infection of neuronal cell lines with prions has been shown to reduce or eliminate bradykinin-
activated increase in intracellular calcium concentration (Kristensson et al., 1993).  
Interestingly, it was found later that this process is linked to the reduction of the inositol 
triphosphate (IP3) second-messenger response (Wong et al., 1996). Increasing slowly over 
time, prion infection causes a dysfunction of voltage gated N-type calcium channels (VGCC) 
(Sandberg et al., 2004). The early release of calcium from the ER through the ryanodine 
receptor (RyR) and the IP3 receptor has been proposed as a mediator of neurotoxicity in 
prion disease (Ferreiro et al., 2008). Alteration of ER calcium homeostasis has also been 
found in prion infection models (Torres et al., 2010). Additionally, increased expression of the 
cytosolic calcium/calmodulin-dependent protein kinase two (CaM kinase II), important for 
long-term potentiation, has been found in prion infected mice (Jin et al., 1999).   
 
Figure 9: Alteration of calcium 
homeostasis upon prion 
infection 
Illustration of prion down- (-) or 
up-regulated (+) Ca2+ dependent 
transporters or mechanisms. 
Affected transporters include 
Ca2+ channels responsive to 
inositol triphosphate (IP3), or 
ryanodine (RyR). Grey dashes 
point to activation events that 
normally take place when Ca2+ 
enters into the cell through 
voltage-gated Ca2+ channels (VGCC), or ionotropic glutamate receptors (GluR). This is the case of 
Ca2+ -activated K+ channels (CaKC) in postsynaptic membranes, and the fusion of synaptic vesicles 
(SV) in presynaptic terminals. The red dash indicates activation of store-operated Ca2+ channels 
(SOC) by depletion of ER Ca2+ stores. Also the expression of CaM kinase II, and of the phosphatase 
calcineurin (CaN), has been found to be affected in some models of prion disease. Conversely, to 
date, no association between alteration of calcium homeostasis and prion infection has been reported 
with respect to the Na+/Ca2+ exchanger (NCX). Simillarly there is no effect either with plasma 
membrane Ca2+-ATPase (PMCA) or mechanisms that control uptake and discharge from the Golgi 
network (not shown). Red and blue dots schematically represent Ca2+ ions and glutamate molecules, 
respectively. MIT: mitochondrion. Figure modified from Sorgato and Bertoli, 2009 with permission from 
Elsevier limited; Rightslink license number: 3485831120729, (Sorgato and Bertoli, 2009).  
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The bidirectional Na+/Ca2+ exchanger (NCX), which exists in three different isoforms (NCX1, 
NCX2, NCX3) and is expressed in neurons and glial cells, plays an important role in 
intracellular free Ca2+ homeostasis, both in physiological and pathological conditions. Under 
physiological conditions, Ca extrusion via NCX is the dominant mechanism when a train of 
action potentials reaches the nerve terminal (forward mode). Under pathological conditions 
such as brain ischemia or A-β exposure (Pannaccione et al., 2012), the antiporter NCX3 has 
shown to be protective (Molinaro et al., 2008), by maintaining Ca homeostasis. However, an 
involvement of NCX transporters in prion disease has not been reported to date (Sorgato and 
Bertoli, 2009).  
 
Manganese Enhanced Magnetic Resonance Imaging 
Paramagnetic contrast agents generate magnetic moment 3-8 orders of magnitude stronger 
than the moment generated with the nuclei and accelerate T1 relaxation (Meier D. et al., 
2012). For example, divalent ion manganese, which can enter excitable cells via a Ca2+ 
transport mechanism, is the basis for Manganese Enhanced Magnetic Resonance Imaging 
(MEMRI) (Silva and Bock, 2008). MEMRI has three major applications: (1) imaging of the 
neuroarchitecture based on the unique properties as an intracellular contrast agent, (2) 
mapping neuronal tracts in the living brain and (3) the demarcation of active brain regions 
(Silva and Bock, 2008). The technique has been used to measure a decline in axonal 
transport rates in an Alzheimer model (Smith et al., 2007). A manganese enhanced signal 
was reported in the cerebellum and hippocampus in the 1D4 mouse model, a cytosolic PrP 
expressing mouse line with corresponding neurodegenerative changes (Faas et al., 2010).  
 
Outline 
The concept of modelling the pathologic induction of neurotoxicity in TSE with antiprion 
antibodies is of interest due to several aspects. First, neurotoxicity is uncoupled from prion 
replication in this paradigm, allowing the investigation of this central hallmark of prion disease 
separate from prion replication. Secondly, this model solves a major biosafety issue in prion 
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research, which is a drawback of many other methods. Finally in the antiprion mediated 
model in contrast to prion inoculation, neurotoxicity is seen after days. 
Here I have investigated whether antiprion mediated neurotoxicity can be used as a new 
bioassay in vivo to assess PrP mediated neurotoxicity. The aim was to develop a fast in vivo 
bioassay for prion disease, which circumvents biosafety issues. I have found MRI to 
represent a very useful technique to assess anti prion mediated neurotoxicity, since it allows 
precise quantification over time of lesion induction.  
Based on this observation, I could demonstrate that antiprion mediated neurotoxicity is PrPC 
expression level dependent and crosslinking independent in vivo. In fact, the latter was 
proposed as the mechanism of antiprion antibody toxicity in previous studies. Here I can 
provide an explanation for this discrepancy.  
Oxidative stress is a crucial pathway that is activated upon antiprion antibody binding in 
COCS. I could verify this in my in vivo system and could additionally identify the NOX 
isoenzyme two as an important resource of ROS production. 
Activation of Calpains points to an increase of Ca2+ in the cytoplasm. Here I provide evidence 
that NCX3 is the source of massive calcium influx upon antiprion antibody administration in 
vivo. Unexpectedly, NCX3 knockout mice had a shorter survival on prion infection than wt 
mice. This difference in the model system could point to important adaptive mechanisms in 
TSE upon chronic deregulation of calcium. 
In our publication we identified the amino terminus as the executer of antiprion mediated 
neurotoxicity. The amino terminus consists of different functional units, which could be 
differentially involved in the induction of prion toxicity. We are now interested in how they 
regulate antiprion mediated neurotoxicity. In the last month of my doctoratal program I was 
working on the establishment of a new testing system that allowed the screening of different 
mutants. For this work I will provide an extended outlook at the end of Part I.  
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Results 
Establishment of MEMRI 
In order to visualize antiprion antibody toxicity in vivo in intact mice, I utilized the MEMRI 
parameters as a template that were established in a previous study (Faas et al., 2010) to 
optimize the scanning protocol. The imaging was performed on a Bruker PharmaScan® with 
a permanent magnetic field of 4.7 T (Figure 10A). To increase the signal to noise ratio, a 1H 
mouse brain receive-only surface coil (Figure 10B) was used in combination with a 
transmission-only body coil. The position of the isoflurane-anesthetized mouse on the 
mouse-bed was optimized to reduce the distance between the receiver and the mouse head 
(Figure 10C and D).  The mouse was warmed with a warming blanket during the scanning 
(Figure 10E). 
 
 
Figure 10: Establishment of scanning parameters.  
(A) Image of the used Bruker PharmaScan® with a permanent magnetic field of 4.7 T. (B) To increase 
the signal to noise, a mouse surface coil was used to limit the spatial extend of the reception (white 
arrow). The black arrow points to the mouse bed. (C) Positioning of the anesthetized animal on the 
mouse bed. The star points to the cannula delivering isoflurane. (D) The surface coil was mounted on 
the mouse bed in a manner to allow maximal reception from the region of interest (here the 
cerebellum). (E) A warming blanket was used to prevent body temperature drop during scanning. (F) 
Representative sagittal image of a T1 weighted 3D-gradient echo sequence with a TE of 6 ms, TR of 
50 ms using 10 averages at a voxel size of 120 μm x 120 μm x 120 μm. The mouse was ip injected 
with 37.7 mg/KG manganese 24 h prior to scanning. (G) The same scanning session and conditions 
were used as in F, with a decreased TE of 2.5 ms and TR of 15 ms to increase T1 contrast.  (H) 
Maximally increased resolution at a voxel size of 78 μm x 100 μm x 156 μm. Images were generated 
within the same session as the images from G and F.  
 
To enable exact volume measurements at a later timepoint, I used a 3D gradient echo 
sequence. Various TE, TR, average and voxel size were tested (Figure 10F and G) and the 
best results were finally achieved with a TE of 2.5 ms, TR of 15 ms, 10 averages at a voxel 
  36
size of 78 μm x 100 μm x 156 μm (Figure 10H). 
Increasing anatomical contrast was found 24 h post intraperitoneal (ip) injection of rising 
single doses between 20–45 mg/KG of Manganese (Figure 11A). Discrimination of the 
cerebellar layers was found to be optimal with higher doses of the contrast agent. In order to 
reduce the toxic effects of manganese at high doses, I decided to utilize a fractionated 
injection protocol (Bock et al., 2008). A regime of six ip injections at 12-hour intervals was 
found to be optimal (Figure 11B).  
 
Figure 11: Fractionated manganese 
doses yield the highest anatomical 
contrast in the cerebellum.  
(A) Representative images 24h post 
injection of increasing manganese 
single doses from 0 to 45 mg/KG ip 
injected into BL6 mice. (B) 
Representative images of mice injected 
with 6 fractions (12h interval) of 30 
mg/KG manganese (upper panel). The 
same mouse was injected with two 
additional fractions of manganese (lower panel). Six fractions were found to be sufficient for 
appropriate contrast. Images were taken 24h after the last injection.  
 
Volumetric quantification of MRI pictures 
Stereotactic injection of antiprion antibodies in vivo induces a focal lesion (Solforosi et al., 
2004). Therefore, volumetric quantification of this lesion seemed feasible. Towards this goal I 
produced eight volume phantoms out of polymer clay with different shapes and sizes (Figure 
12A). In order to calculate the volume given the density, I weighted the phantoms. These 
were imaged with the established T1 weighted 3D gradient echo scan. From these images, I 
quantified the volume of the phantoms by either manual quantification using the ParaVision 
software (Version 5,Opl3, Bruker) or semi-automated segmentation by utilizing the Myrian® 
3D diagnostic workstation. A regression analysis of the MRI based measurements was 
performed against the initial calculated volumes, which demonstrated a high accordance for 
both methods (Figure 12B and C). The volume difference estimated by the two models is 
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minimal (Figure 12D). Further analysis is based on the manual quantification using the 
ParaVision software. 
 
 
Figure 12: The established 3D gradient echo sequences can be used for an exact volumetric 
quantification.  
(A) Volume Phantoms were generated with polymer clay. Upper row shows cube- shaped and the 
lower row angular-shaped objects of different sizes. (B) Prior to MRI measurement volume phantoms 
were hardened in the oven and embedded into low melting agarose. (C) Linear regression analysis of 
manual volume measurements (R2: 0.992; slope: 0.909 ± 0.032). (D) Linear regression analysis of 
semi-automated quantification with Myrian® (R2: 0.994; slope: 0.912 ± 0.029). (E) Linear regression 
analysis of Myrian® data versus semi-automated quantification (R2: 0.998; slope: 1.001 ± 0.018). 
 
Intra-cerebellar injection of antiprion antibody leads to rapid lesion induction 
Intracerebral stereotactic injections were used to investigate antiprion mediated toxicity in 
vivo in a previous study (Klöhn et al., 2012; Solforosi et al., 2004; Song et al., 2008). These 
studies used histology as a qualitative read-out without quantitative analysis. After the 
successful establishment of the MEMRI protocol and volumetric quantification, we decided to 
use the system to visualize and quantify antiprion mediated lesion induction over time in vivo. 
PrP-overexpressing mice (tga20) (Fischer et al., 1996) were ip injected with fractions of 
manganese prior to antibody injection. I used a motorized stereotactic frame to inject 6 μg 
(dissolved in 2 μl, 20 μM) of the antiprion antibody POM1 or immunoglobulin G (IgG)-control 
into the fourth folium of the cerebellum (Figure 13A) of tga20 mice. After recovery from 
anesthesia, an ataxic gait was seen in POM1 injected mice in contrast to IgG injection, where 
ataxia was not observed. These symptoms were strongest within the first hours after injection 
and disappeared within two days. Upon MEMRI examination, a large hypointense signal was 
found 24 and 72h post intracerebral injection (p.i.i.) on MRI examination (Figure 13B and E). 
Volume of signal alteration was greatest at 24h decreased somewhat thereafter (Figure 
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13E). In order to control for anatomical differences of cerebellar size between mice, the 
lesion volume was normalized against cerebellar volume (here and henceforth). As the 
previous investigation of antiprion toxicity in vivo is based upon histological analysis mice 
were euthanized after the last scan and the cerebellum was examined histologically with 
H&E stained paraffin step sections (100 μm steps). On comparison of the H&E sections 72h 
p.i.i. with the corresponding MRI image plane 24h p.i.i., I found good correlation in assessing 
the area of lesion induction (Figure 13B). On higher magnification, numerous granular cells 
with pyknotic nuclei were found within the lesion (Figure 13D). The morphological description 
is similar to previous reports (Solforosi et al., 2004). 
To control for the possibility of vehicle contamination inducing toxicity, Prnp°/° was 
additionally injected with POM1. In contrast to tga20 mice, evidence of lesion induction other 
than needle tract was not found in these mice (Figure 13C and E). As lesions were found to 
be maximal at 24h, I performed additional early time-point scans 4h p.i.i. A marginal 
hypointensity could be recorded at this time point in tga20 mice (Figure 13D), indicative of 
rapid lesion induction.  
The narrow lamina of hyperintense signal, hypothesized to correspond to the Purkinje cell 
layer, (Faas et al., 2010) is still present at 72h (Figure 11D). This observation is unexpected 
if the neurons were to undergo cell death; however, Purkinje cells in tga20 mice lack 
transgene expression (Fischer et al., 1996) and therefore escape antibody mediated toxicity. 
Thus, the persistence of the hyperintense lamina confirms that the signal likely arises from 
Purkinje cells. 
Antiprion antibody mediated toxicity have been found to be prion protein expression level 
dependent. Thus, I next injected POM1 intracerebral into wt mice (BL6 is not otherwise 
stated). A six fold smaller hypointense lesion could be detected 24h p.i.i (Figure 13D), 
illustrating the antigen expression level dependence of antiprion antibody induced toxicity in 
vivo (Figure 13E).   
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Figure 13:  MEMRI volumetry is an efficient tool to quantify antiprion antibody mediated toxicity  
(A) Schematic representation of the murine cerebellum. The crosshair (red) denotes the site of the 
injection. (B) MEMRI scans showed a hypointense lesion in the POM1-treated (6 μg in 2 μl) mouse 
24h post intracerebellar injection in contrast to IgG control injection (left panel). Structural tissue 
alterations are found on corresponding low-resolution coronal haematoxylin & eosin (H&E)-stained 
72h p.i.i. micrographs. (C) Representative sagittal MRI scans before injection (prescan) and at 4h, 
24h, and 72h after POM1 injection in tga20 and Prnpo/o mice. In tga20 mice, incipient edema was 
recognized as marginal hypointensity already at 4h. After 24h and 72h, hypointense lesions were fully 
developed and involved several folia. In contrast, POM1 injected Prnpo/o mice showed only a small 
focus of hypointensity along the needle tract. (D) Representative images of POM1-treated wild-type 
(WT) and tga20 mice (left panels) 72h post intracerebellar injection. Yellow dashed lines delineate the 
lesions. Histology (middle and right panels) revealed CGC destruction (asterisks) and edema. Inset 
rectangles in the middle images indicate the regions magnified in the corresponding panels on the 
right. Tga20 Purkinje cells (arrow), which do not express PrPC, were largely preserved. (E) Lesion 
volumes at 4h, 24h and 72h post intracerebellar injection as percentages of total cerebellar volumes in 
wild type, tga20 and Prnpo/o. Grey: control injections (6 μg, mean±s.d., n=4 except for Prnpo/o at 72h 
n=3, tga20 at 4h and 24h n=6,one-way ANOVA with Dunnett’s post-hoc test). 
 
To gain additional histological information, I euthanized some of the mice at earlier or later 
time point than 72h post injection. As already detected on the MEMRI images, early 
morphological alterations with chromatin condensation can be found as early as 5h (Figure 
14A). Interestingly these early alterations have not been detected in the pervious study in wt 
mice, which may be an indication that prion protein expression levels have an influence on 
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the kinetics of lesion induction. At 24h mainly spongiosis and loosening of the tissue were 
seen, most likely indicative of edema formation (Figure 14B). The formation of true 
spongiform vacuoles was less well-defined. Mild macrophage infiltration as a minimal 
inflammatory reaction was noted (Figure 14B). A strong reactive astrocytic reaction was seen 
initial (Figure 14B) and later prominent Bergmann gliosis (Figure 14C).  
 
 
 
Figure 14: Representative haematoxylin-eosin sections from POM1-injected tga20 and Prnpo/o 
mouse cerebella.  
(A) Chromatin condensation in cerebellar granular cells (black arrowhead) was seen as early as 5h 
post-injection. (B) Progression to edema and macrophage infiltration (black arrow) was seen after 24h. 
(C) One week post injection, prominent loss of granular cell neurons and brisk Bergmann glia 
proliferation (black arrow) were evident. The differential survival of Purkinje neurons (white 
arrowheads) is consistent with the lack of PrPC expression in Purkinje neurons of tga20 mice.  
 
Difference in cerebellar volume is dependent on genetic background and not on prion 
protein expression  
 
After normalizing the lesion size against cerebellar volume, I quantified the cerebellar volume 
of mice expressing PrPC at different levels. For Zürich-I Prnp°/° (mixed genetic background 
BL6 and 129, BL6.129) I found a mean cerebellar volume of 66.2 mm3, which was 
significantly larger than the mean cerebellar volumes of BL6.129-tga20 (mean: 53.8 mm3, 
Figure 15A). To assess if the mixed genetic background was confounding the results, I 
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quantified the cerebellar volume of Prnp°/° backcrossed for several generation with BL6 mice, 
which were found to be comparable to BL6.129-tga20 mice. Additionally, cerebellar weights 
between coisogenic Edinburgh 129-Prnp-/- (Manson et al., 1994) and its 129-Prnp+/- and 129-
Prnp+/+ littermates did not differ (Figure 15B). The influence of 129 background on cerebellar 
volume is illustrated by the comparable cerebellar weights of BL6.129-Prnp°/° and 129-Prnp-/- 
in contrast to BL6.129-tga20 (Figure 15B). The weight measurements of the cerebella 
correlate closely with the measured volumes based on the MEMRI dataset. 
 
Figure 15: Genetic background 
confounds cerebellar volume between 
tga20 and Prnp°/° 
(A) Volumetric measurement of cerebellum 
based on MEMRI enhanced scans of male 
tga20 (n=19), Prnp°/° (n=4) mice on a 
mixed BL6.129 background (violet), of 
Prnp°/° backcrossed for several generation 
to BL6 (n=3) and of BL6 inbred mice (n=9) 
and one 129 mouse. Whereas there is a 
significant difference between BL6.129-
tga20 and BL6.129-prnp°/°, there is no 
difference between BL6.129-tga20 and 
BL6-Prnp°/°. Cerebellar size in BL6.129-
Prnp°/° mice on a mixed genetic 
background are potentially comparable to inbred 129 mice as indicated by a single measurement 
(One-way ANOVA with Tukey’s post-hoc test). (B) Cerebellar weight of BL6.129-tga20, BL6.129-
Prnp°/° males and of 129-Prnp-/- (Edbg) separated according to gender. Whereas a significant 
difference between BL6.129-tga20 and BL6.129-Prnp°/° was found, there is no difference between 
cerebellar weights of 129-Prnp-/- in comparison to their 129-Prnp+/+ littermates (One-way ANOVA with 
Tukey’s post-hoc test). 
 
Antiprion mediated neurotoxicity is crosslinking independent and neuronal PrPC 
expression dependent in vivo 
 
In contrast to the initial report (Solforosi et al., 2004), antibody mediated toxicity has been 
found to be independent of PrP crosslinking in cerebellar slice cultures (Sonati, 2013b). 
Therefore, I injected ScFvPOM1 (2 μg in 2 μl, 40 μM) intracerebellar into BL6, Prnp°/° and 
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tga20 mice. As for whole antibody, an expression level dependent lesion induction was found 
(Figure 16). To demonstrate that vehicle components are not responsible for lesion induction, 
I additionally tested ScFvPOM1 pre-incubated with its corresponding antigen (recombinant 
murine PrP, rmPrP), which was was found to be innocuous (Figure 16).  
Since antiprion mediated neurotoxicity was found to be epitope specific in cerebellar slice 
cultures, I next administered the ScFvPOM2 intracerebellar into tga20 mice without a 
hypointesive lesion induction (Figure 16). 
 
Figure 16:  Antiprion mediated lesion induction in vivo 
is epitope specific and independent of PrP crosslinking 
Lesions occurred in tga20 (n=4) and wild-type (n=4) mice 
after injection of ScFvPOM1 (2 μg) but not after ScFvPOM2 
(n=4), or ScFvPOM1 (2 μg) preincubated with recombinant 
murine PrP (rmPrP, residues 23–230) (molar ratio 1:5, 24h, 
n=4). ScFvPOM1-treatment was innocuous to Prnpo/o (n=3) 
mice:  no recombinant prp added (mean±s.d., two-tailed 
Student’s t-test). 
 
 
 
PrP expression on neurons is required for antiprion mediated neurotoxicity, as demonstrated 
by the relative preservation of Purkinje cell in tga20 mice. To investigate if PrP expression on 
neurons is sufficient for lesion induction in vivo, I utilized NSE-PrP mice, which express PrP 
under the neuron-specific enolase promoter (Radovanovic et al., 2005). Upon ScFvPOM1 
injection (3 μg in 2 μl), significant lesion induction was found in four mice in contrast to 
Prnp°/° mice (Figure 17).  It should be emphasize that the size of lesions with a mean of 
6.8% of the cerebellar volume is significantly larger than the mean of lesion induction in wt 
mice (at 3 μg, Figure 18) despite equal PrP expression (p=0.0003) (Sonati, 2013b). One 
explanation could be that other cellular elements such as glial cells absorb less neurotoxic 
antibody.  
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Figure 17: Neuronal prion protein expression is 
sufficient for lesion induction. 
MEMRI volumetry (24h post intracerebellar injection) of 
neuron-specific enolase (NSE) NSE-PrP (NSE promoter 
driving specifically neuronal PrP expression) (n=4) and 
Prnpo/o (n=7) mice injected with ScFvPOM1 (3 μg; 
mean±s.d., two-tailed Student’s t-test). 
 
 
 
 
CC2 depleted mice are hypersensitive to antiprion mediated neurotoxicity 
Next I injected ScFvPOM1 (3 μg in 2 μl, 60 μM) into the cerebella in mice that express a PrP 
form with a larger deletion in the FT including the OR, the PrPΔ32–93 (Figure 18). As in COCS 
these mice were found to be resistant to antiprion mediated toxicity in vivo. In contrast 24 h 
post injection of ScFvPOM1 large hyperintensive lesions were found in PrPΔ94-110 (Figure 18). 
These mice are CC2-depleted and express the construct in similar amounts as wt mice 
(Sonati, 2013b). In addition to mild ataxia, these mice presented with repetitive movements 
of the forelimbs. MEMRI scans 48h post injection revealed a three-fold increase in lesion 
size. 
 
 
Figure 18: Depletion of larger segments of the FT 
prevents antiprion mediated neurotoxic induction in vivo 
MEMRI volumetry 24h post intracerebellar injection of 
ScFvPOM1 injected into PrPΔ94–110 (L52, n=3), PrPΔ32–93 (n=5) 
and wild type (n=8). An additional scan for the PrP(Δ94–
110) mice got performed 48 h post injection, where a 
threefold increase in lesion size was found (mean±s.d.; two-
tailed Student’s t-test). 
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Monovalent fragment antigen mediates neurotoxicity 
Initially no toxicity was observed upon injection of monovalent F(ab) fragments from toxic anti 
prion antibodies in vivo when the antibody was injected in the same dose as the whole 
antibody (Solforosi et al., 2004). Thus I injected F(ab)1POM1 and F(ab)1POM19 at a 
concentration of 60 μM (6 μg in 2 μl, 1:3 molar ratio in comparison to holoantibody injection) 
intracerebellarly into BL6 mice. Since whole antibody has two binding sides, a higher 
concentration was chosen. Upon MEMRI volumetric analysis, significant lesion induction was 
found only for F(ab)1POM19 (Figure 19). F(ab)1POM1 however, induced small hyperintense 
lesions (Figure 19). It is likely that F(ab)1POM1would have induced significant toxicity at 
higher concentrations, indicative of a different kinetic of F(ab)1  fragments in contrast to whole 
antibodies and single chains.  
Figure 19: Significant lesion 
induction is found upon injection 
of F(ab)1POM19, but not upon 
F(ab)1POM1 injection 
Intracerebellar injection of 
F(ab)1POM1 led to the induction of 
small hypointense areas (star) in 
two out of five mice. Volumetric 
quantification against IgG injection 
revealed no significant difference. In 
contrast, F(ab)1POM19 injection 
(n=8) led to significant lesion induction in contrast to IgG control (one-way ANOVA with Tukey’s post-
hoc test). 
 
NADPH oxidase 2 is the major resource of reactive oxygen species 
Ascorbate and N-Acetyl Cysteine (NAc) was neuroprotective against POM1 induced 
neurotoxicity in cerebellar slice cultures. I therefore administered the antioxidant acetylated 
hydroxytyrosol (AcHyt), which has been shown to cross the blood-brain barrier (Granados-
Principal et al., 2010), in the drinking water to tga20 mice. Seven days after the start of the 
treatment, I injected ScFvPOM1 into the cerebellum and found significant lesion induction in 
only one of six AcHyt treated tga20 mice (Figure 20A and B).  
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The compound 1400W blocking the NOS 1 and 2 has been found to be non-protective in 
antibody mediated neurotoxicity ex vivo (Sonati, 2013b). In contrast, the NOX2 inhibitor 
diphenyleneiodonium chloride (DPI), suppressed a superoxide spike induced in antiprion 
treated slices, indicative that the superoxide source are NADPH oxidases (Sonati, 2013b). I 
therefore utilized the NOX2 deficient mice (NOX2°/°) (Sorce et al., 2012) to study the 
involvement of this electron transporter upon neurotoxic antiprion antibody injection in vivo. 
Significantly smaller lesions developed in NOX2°/° mice upon POM1 injection than in wild 
type control (BL6J; Figure 20C). 
Figure 20: ROS are major mediators of 
antiprion mediated neurotoxicity in vivo 
(A) Representative H&E histology of mice 
pretreated with acetylated hydroxyltyrosol and 
injected with ScFvPOM1. Haematoxylin-eosin 
stained sections of mouse cerebella. Whereas 
vehicle-treated mice developed large areas of cell 
death around the site of injection (yellow dashed 
line), only small lesions were visible in treated 
mice in the immediate vicinity of the needle tract 
(yellow asterisk). Rectangles indicate the position 
of high magnification pictures shown in the panels 
on the right. (B) Tga20 mice 24h post 
intracerebellar injection of ScFvPOM1 (2 μg) and 
pre-treated with AcHyt (mean±s.d., n=56, one-tailed student t-test. P=0.013). (C) MEMRI volumetry at 
24h post intracerebellar injection of ScFvPOM1 (3 mg) injected into Prnpo/o (n=7), wild-type (n=5) and 
NOX2-deficient (n=11) mice (mean±s.d., one-tailed Student’s t-test). 
 
Hippocampal lesion induction can best be visualized with DWI 
Since distinct prion strains target different brain regions, we therefore were interested in 
injecting antiprion antibodies in brain regions other than the cerebellum. Hippocampal lesion 
induction has been previously described (Solforosi et al., 2004) and allows simultaneous 
bilateral injection. The latter is an advantage as control injections can be performed in the 
same mouse, thus drastically reducing the number of animals needed for experiments. 
After injecting POM1 into different coordinates, including injection into the cornu ammonis 
region one (CA1) as previously performed (Solforosi et al., 2004), the stereotactic 
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coordinates anterior-posterior (AP): -2; middle line (ML): 1.7; dorsal-ventral (DV): 2.2 from, 
allowing injection between the cornu ammonis region three (CA3) and the dentate gyrus 
(DG) were chosen for further injections (Figure 21A). Forty-eight hours after administration 
into the left side of POM1 or D13, a loss of manganese signal was found not seen upon IgG 
control injection (Figure 21B and C). While MEMRI contrast in the dentate CA3 was found to 
be optimal for quantification, less manganese contrast is seen in the cornu ammonis regions 
2 and 3 (Figure 21C). Therefore, estimation of the total lesion size was found to be difficult 
and I decided to quantify the manganese enhanced DG and CA3 volumes on both sides 
(Figure 21B). As a technical control, I quantified the contralateral non-injected hippocampus.  
Histological examination after 38 h revealed neurotoxic induction corresponding to the region 
that showed reduction of manganese contrast (Figure 21C).  
Figure 21: MEMRI is limited in the 
assessment of hippocampal lesion 
induction 
(A) Schematic representation of the 
murine hippocampus. Crosshairs (red) 
denote the site of injection. CA1-3: 
Cornu ammonis sectors 1-3. DG: 
Dentate gyrus. (B) Volumetric 
assessment of the size of CA3 and DG 
(mm3) ipsilateral (il) and contralateral 
(cl) to antibody injection in tga20 mice 
(48h post injection). Both POM1 and 
D13 led to a reduction in CA3 volume 
ipsilaterally. (Data are presented as 
mean ± s.d., n=4, One-way ANOVA with Dunnett’s post-test, *** P<0.001, *P<0,1) (C) MEMRI (left 
panels) showing loss of the CA2-3 contour and appearance of a hypointense lesion ipsilateral (il) to 
the site of POM1 and D13 injections, whereas the contralateral site (cl) did not show lesions after IgG 
injection. Histological analysis 48h post injection (right panels) showed loss of NeuN-positive neurons 
in the dentate gyrus and in the CA3 sector after POM1 and D13 injection.   
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MEMRI based hippocampal lesion quantification is technically limited and the repetitive ip 
injections needed for adequate contrast are challenging for experimental animals. Therefore, 
I assessed the use of DWI in the antibody mediated neurotoxicity model in vivo. Gradient-
echo sequences instead of spin-echo sequences were established due to troublesome 
artefacts in the latter. As early as one hour post injection of the F(ab)1POM1 (8 μg in 2 μl, 80 
μM), diffusion restriction could be recorded in the DG and CA3 regions of tga20 mice (Figure 
22A). The hyperintensive signal appears as a sharp line corresponding to the shape of the 
neuronal layer, mainly of the DG and to some extends the CA3. No such signal alterations 
were observed contralateral to the injection site with the same dose of F(ab)1POM1 
preincubated with its specific antigen. Four hours post injection, the signal was similar in size 
but blurred (Figure 22A and B). As DWI images are influenced by differences in T2 contrast, 
this blurring is most likely induced by extra-neuronal edema formation. For analysis, I have 
chosen the volumetric quantitative analysis previously described for MEMRI quantification. 
Lesion volume was normalized over hippocampal volume. The analysis demonstrated 
significant signal alterations at both time points (Figure 22B). Upon POM1 injection a mean 
of 2 mm3 of the DG and CA3 region were damaged as assessed by MEMRI. At one-hour 
post injection, a mean lesion induction of 2.8 mm3 was found. These data demonstrate that in 
vivo, monovalent F(ab)1 fragments induce similar damage at a four times higher 
concentration than whole antibody (80 μM F(ab)1 POM1 in contrast to 20 μM POM1). As 
whole antibody has two binding sites, a two fold higher concentration would have been 
expected. This is probably explained by kinetic properties of the F(ab)1 fragments like 
diffusion.  
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Figure 22:  Early 
Diffusion restriction is 
seen after F(ab)1 POM1 
DG injection in tga20 
mice 
(A) As early as one hour 
post injection of F(ab)1 
POM1 into the DG of 
tga20 mice a sharp 
hyperintense line is 
seen on DWI images. The signal developed into a hyperintense area 4h post injection. No such 
hyperintense signal was found upon injection of F(ab)1 POM1 preincubated with its rmPrP into the 
contralateral side. (B) Volumetric quantitative analysis revealed a significant lesion induction at both 
time points. The standard deviation in this experiment was: 7.6. Grey: control injections (8 μg, 
mean±s.d., n=3, one-way ANOVA with Tukey’s post-hoc test). 
 
Non-significant lesion induction was found upon injection of 6 μg F(ab)1 POM1 into the 
cerebellum of BL6 wt mice. To investigate if significant toxicity can be induced upon injection 
of higher concentration, I injected 8 μg of F(ab)1 POM1 into the hippocampus. As in tga20 
mice, a hyperintensive lesion was found one-hour post injection in contrast to the control 
injection on the contralateral side, which blurred out over 24h (Figure 23A). However, 
quantitative analysis of lesion volume, on the basis of a small group size of n=3, revealed a 
slight trend but no significant lesion induction (Figure 23B). The lesion size in one mouse 
was with 18% definitely greater than the control injection (3%), indicative for a negative 
effect. The high variance seen may again be related to differences in diffusion kinetics.  
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Figure 23: Lesion induction upon 8 μg F(ab)1 POM1 injection into the DG of BL6 mice 
(A) Diffusion restriction recorded in selected mice 1-hour and 24-hour post injection after 8 μg F(ab)1 
POM1. On control injection to the contralateral side, F(ab)1 POM1 preincubated with rmPrP, no 
hyperintense signal was found within the parenchyma. One hour post injection, minimal hyperintense 
signal alterations were recorded in the ventricle wall (star) upon control injection. (B) The induced 
lesion in n=3 mice was not significant upon volumetric analysis. The standard deviation in this 
experiment was: 7.3%, one-way ANOVA with Tukey’s post-hoc test 
 
Calpain is activated upon antiprion mediated toxicity in vivo, but neither Calpastatin 
overexpression nor treatment with E64d was protective  
The involvement of the cysteine protease calpain in driving neurotoxicity was demonstrated 
in prion infected COCS (Falsig et al., 2012). In the antibody mediated toxicity model, 
activation was demonstrated with the detection of the characteristic α-fodrin (α-spektrin) 
cleavage pattern at 145 kDa (Wang, 2000), as well as the pharmacological inhibition with the 
cysteine-protease Calpeptine, an aldehyde inhibitor. α-fodrin immunoblot on cerebellar 
homogenates from either ScFvPOM2 or ScFvPOM1 injected tga20 mice, revealed identical 
characteristic proteolytic fragments pointing to calpain activation (Figure 24A). Therefore, I 
decided to perform a treatment experiment with the cell-penetrating calpain inhibitor E64d 
(Loxastatin) an oxirane inhibitor (Mehdi, 1991). The substance has previously been 
successfully used to inhibit neurotoxicity in prion infected COCS (Falsig et al., 2012) and 
could reduce infarct volume from middle cerebral artery occlusion in vivo (Tsubokawa et al., 
2006). I decided to administer E64D (5 mg/KG) or vehicle ip 4 hours before induction of 
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antiprion mediated neurotoxicity using 2 μg of ScFvPOM1 and analyzed lesion induction based 
on MEMRI volumetry. No significant difference was found between the treated versus the 
untreated group (Figure 24B).  
 
 
Figure 24: Immunostaining for 
Fodrin indicate calpain 
mediated α-cleavage  
(A) Western blots of cerebellar 
homogenates from ScFvPOM1 
injected tga20 mice (24 hours 
pi) showing increased 145 kDA 
α-fodrin cleavage in contrast to 
ScFvPOM2 injected. Full-length 
fodrin at 240 kDa. (B) Tga20 mice were pre-treated with E64D (5mg/KG) or vehicle ip 4 hours, before 
cerebellar lesion induction upon stereotactic injection with scFVPOM1 (2 µg). Lesion reduction was 
not observed in the pre-treated group compared to the vehicle control upon MEMRI examination. 
(mean±s.d., one-tailed Student’s t-test) 
 
The use of pharmacological inhibitors to demonstrate the involvement of mediators can be 
challenging in vivo, since therapeutic doses have to be reached at the site of interest, i.e., the 
injection site in the brain. In addition, such compounds often interact with more then one 
mediator. If available, testing with transgenic mice can offer advantages. The human 
calpastatin (CAST) transgenic mouse (hCast) overexpresses human CAST, an endogenous 
calpain inhibitor under the Thy1.1 promoter (Rao et al., 2008). Of note, experiments with 
these mice showed a neuroprotective function for calpastatin mimetics in Alzheimer Disease. 
Since antibody mediated lesion size is small in wild type mice expressing PrPC, we crossed 
these mice with tga20 and generated heterozygous double transgenic mice (hCast+/--tga20+/-
). Upon injection of POM1 (6μg) into the DG of hCast+/--tga20+/-, in contrast to littermate 
controls, hCast-/-- tga20+/- showed no significant difference in lesion volume upon MEMRI 
(Figure 25). However, there was a trend towards protection.  
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Figure 25: MEMRI analysis reveals a trend 
towards lesion reduction in calpastatin 
overexpressing mice 
Double heterozygous transgenetic mice 
overexpressing human calpastatin and PrPC were 
injected on one side with POM1 (6 μg in 2 μl) and 
lesion induction was quantified with MEMRI 
volumetry. A trend towards less manganese signal 
from DG and CA3 was found, but the differences 
between the groups were not significant. (mean±s.d., 
one-tailed Student’s t-test) 
 
 
 
Since MEMRI volumetry is technically limited in estimating lesion size, I repeated the 
experiment with the established DWI read-out. Diffusion restriction induced by POM1 
injection was comparable in heterozygous hCast+/--tga20+/- and in littermate controls hCast-/--
tga20+/- (Figure 26A). To assess if hCalpastatin expression was sufficient for calpain 
inhibition, I investigated α-fodrin cleavage and found the characteristic fragments in hCast+/--
tga20+/- and controls (Figure 26B), indicating insufficient inhibition of calpain upon calpastatin 
expression.  
 
Figure 26: Calpastatin overexpressing is not protective upon POM1 injection 
(A) Injection of POM1 (6 μg, 10 μM) in human calpastatin overexpressing mice (hCast+/-) crossed with 
tga20 (tga20+/-) induced a lesion comparable to that of injection into transgene negative littermates 
hCast-/-, one-way ANOVA with Tukey’s post-hoc test) (B) Western blots of both hCast+/- positive and 
negative mice injected with POM1 (24h p.i.) show increased 145 kDA α-fodrin cleavage in contrast to 
the contralateral side, where the lesion was blocked with recombinant rmPrP.  
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The antiporter sodium-calcium exchanger isoform 3 is a potential source of Ca2+ influx 
The activation of calpains from their pro-enzymes is an indicator of elevated Ca2+ levels in 
the micromolar range (Wang, 2000). After extensive pharmacological screening for the 
involvement of Ca2+ channels in our previous studies (Hermann et al., 2015; Sonati, 2013b), 
no protective function was found with respect to the  inhibition of  NMDA, AMPA/kainite, and 
L-type calcium channels. However, inhibition of the reverse mode of the sodium-calcium 
antiporter isoform 3 (Falsig, unpublished) has been found to be protective. Therefore, I 
injected POM1 into the left DG of NCX3°/° mice (Sokolow et al., 2004) or littermate control 
NCX3+/+, and all mice were injected contralaterally with POM1 (3 μg) pre-incubated with 
rmPrP. Progression of lesion volume assessed by DWI was slower than upon F(ab)1 POM1 
(8μg) injection but was significant in NCX3°/° 24h post injection (Figure 27A and B). No 
significant lesion induction was found in NCX3°/° mice (Figure 27B) compared to the control 
injection. Assessment with TUNEL staining revealed sparse apoptotic nuclear cells in 
NCX3°/° but numerous in NCX3+/+ (Figure 27C). A second experiment using F(ab)1 POM1 
demonstrated the same effect with no evidence of lesion induction in contrast to littermate 
control (Figure 27D and E). These data point to an early influx of Ca2+ through NCX3 
(reverse mode) mediating neurotoxicity in the antiprion antibody model. 
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Figure 
27: NCX3 deficiency protects from anti-prion mediated neurotoxicity 
(A, B) Small lesions developed after POM1 (6 μg) injection into the left hippocampus of NCX3-/- (star) 
compared to wt littermate controls, where a constant increase in lesion size was seen at 1, 4 and 24h 
post injection. As a control, POM1 was preincubated with rmPrP and injected into the right 
hippocampus. A) Representative images of diffusion-weighted images (DWI) B) Volumetric analysis 
reveals significant lesion induction 24h post POM1 injection. Data are presented as mean ± s.d., n=3, 
One-way ANOVA with Dunnett’s post-test, *P<0,1. (C) Tunel staining 24h post injection from mice 
shown in A. Photographs of the endplate of the hippocampus near the needle tract are taken at high 
magnification. No apoptotic cells were found upon control injection. Few cells with positive nuclear 
fragmentation are seen in NCX3°/° (white star), not comparable to NCX3+/+ where numerous apoptotic 
cells are found in a significantly larger area. (D) No diffusion restriction was found 24h post 8 μg 
Fab(1)POM1 injection into NCX3°/° mice. (E) Significant lesion induction was found in NCX3-/- littermate 
controls, in contrast injection of Fab(1)POM1 into NCX3°/° was innocuous. Data are presented as mean 
± s.d., n=3, One-way ANOVA with Dunnett’s post-test, **P<0,01. 
  54
 
We were now interested in assessing the role of NCX3 upon infection and inoculated NCX3 
defined mice intracerebrally with the prion strain RML (30 µl, diluted). Unexpectedly, NCX3°/° 
mice showed a modest, but significant reduction of survival in contrast to BL6/Hsd2 control 
mice (Figure 28). Hence, upon chronic prion inoculation, the antiporter seems to exhibit a 
protective effect on calcium homeostasis.  
 
Figure 28: NCX3 expression is protective upon prion inoculation 
Survival curves of NCX3°/° (median 50 dpi) and BL6/Hsd2 mice (median 56.3 dpi) mice infected with 
RML prion. NCX3 expression is significantly protective upon prion infection. Results were analyzed 
using a Mantel-Cox log-rank test; n=8 NCX3°/° n=6 BL6/Hsd2. 
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Discussion 
MRI volumetry is a valuable tool for in vivo quantification of antiprion mediated 
neurotoxicity 
In order to investigate antiprion antibody mediated neurotoxicity in vivo, I developed a MRI 
based quantification. This allows visualization and precise analysis of differences in lesion 
size over time. While I first used MEMRI, I switched to DWI to avoid repetitive manganese 
injections. 
We chose MEMRI in the beginning not only because of its extraordinary contrast but also 
because of its functional properties. The activation of calpains in the antibody-mediated 
toxicity is indicative of Ca2+ influx into the neurons. Manganese can enter certain activated 
Ca2+ channels, thus we hypothesized that hyperintense signals from manganese enhanced 
the visualization of neurons.  Instead, I recorded a hypointense signal as early as four hours 
post injection. This signal reflects edema formation rather than the loss of signal from 
enhanced neurons, since it disappeared over time. I can further support the hypothesis that 
Purkinje cells take up most of the manganese (Faas et al., 2010), based on the observation 
that preserved non PrP expressing manganese enhanced Purkinje cells can still be detected 
in POM1 lesions. 
Diffusion weighted imaging is one of the additional tools used in the clinic for the diagnosis of 
CJD and is widely used for other acute neurological diseases like stroke. Here I could 
demonstrate massive and early diffusion restriction upon toxic antiprion antibody injections. 
This signal was found to corelate well with the induction of neuronal death as assessed by 
TUNEL staining. Besides being less invasive than MEMRI, DWI was found to be useful as an 
early marker of antibody mediated toxicity and the contrast to noise of the lesion signal is 
excellent for volumetric quantification. Strikingly diffusion restriction could be monitored as 
early as one hour post intracerebral injection of high doses of F(ab)1POM1.  
Acute nerve cell loss is likely the main morphological correlate of diffusion restriction in CJD 
patient rather than spongiform vacuole formation.  
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Data from in vivo experiments verifies the COCS experiments 
Antiprion mediated toxicity has been rigorously investigated ex vivo in a complex cellular 
environment by the use of COCS. However, this model system does not reflect the complete 
in vivo situation, where there is a circulation and an intact inflammatory system. Thus, a 
major goal of this work was it to verify the central ex vivo findings in an in vivo system and to 
compare the two models.  
The kinetics of neurodegeneration differs slightly between the in vivo and ex vivo system. 
Whereas pyknotic nuclei were found as early as 4 hours post injection in the in vivo model, 
nerve cell loss quantified by propidium iodide staining and NeuN morphometry was found to 
be maximal at 3 and 7 days respectively. I speculate that two reasons contribute to this 
difference. The concentration for chronic antibody treatment was 0.067 mM; however, I 
injected the antibody at a concentration of 20 mM. Although the antibody immediately 
diffuses within the brain, higher peak concentrations are most likely reached at the site of 
injection that influences the neurotoxic kinetics. Additionally, organotypic slice cultures 
develop a relatively thick astrocytic scar, which possibly hinders antibody diffusion. 
The major hallmarks of antiprion mediated neurotoxicity could be verified in vivo. I found the 
induction of neurotoxicity to represent a specific target effect. No lesion occurred upon 
injection into PrPC deficient mice and the toxicity could be blocked upon pre-incubation of 
toxic POM1 antibody with rmPrP. In the in vivo model, the second control is important. I 
found that Zürich-I B6.129-Prnp°/° have enlarged cerebelli in contrast to B6.129-tga20, 
potentially affecting the target point of the stereotactic injections. Furthermore, I could 
demonstrate that the neurotoxic induction is gene dosage dependent in vivo. 
In the first report antiprion mediated neurotoxicity was speculated to be cross-linking 
mediated. This was based on the observation that F(ab)1 fragments of the neurotoxic 
antibody D13 are innocuous when administered at the same concentration as whole 
antibodies (Solforosi et al., 2004). Here I could demonstrate that F(ab) fragments of toxic 
antiprion antibodies induce neurotoxicity in vivo. However, the kinetics is shifted and higher 
concentrations are required to induce the same negative effect as observed with whole 
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antibody administration. This has not been observed ex vivo where F(ab) fragments showed 
to be neurotoxic at comparable concentrations. It is likely that the diffusion and clearance of 
Fab fragments in vivo is higher in comparison to whole antibody injection, thus explaining this 
difference. Interestingly, this observation could not be confirmed for single chain antibodies, 
which I found to be neurotoxic at comparable concentrations. Besides solving this 
controversy, this observation demonstrates that the toxic effect is dosage dependent. 
As predicted for the innocuousness of FT ligands, POM2 was found to be non toxic when 
injected at the same dosages as the toxic antiprion antibodies POM1. F(ab)1POM19 in 
contrast was neurotoxic. Thus, like in the ex vivo studies, antibody mediated neurotoxicity 
was found to be epitope specific.   
To address the molecular function of PrP, a series of partially deleted Prnp variants was 
generated and expressed in cultured cells and in mice (Aguzzi et al., 2008). I could 
demonstrate that intracerebral injection of toxic antiprion antibodies in mice expressing the 
PrPΔ32-93 deletion mutant is innocuous, such as predicted from the slice culture experiments. 
Interestingly, CC2 depleted mice were not only susceptible to antiprion mediated toxicity, and 
compared to wt expression level developed increased lesion size that progressed even after 
24 hours.  
 
Does the model mimic the pathologic interaction of PrPSC with PrPC? 
My work demonstrates that modelling the pathologic interaction of prions with PrPC shows 
investigative potential, since it circumvents biosafety issues and represents a rapid assay in 
contrast to inoculation experiments. Thus, it could be widely used to generate and test 
hypotheses. However, it is unclear whether this model can be used to model neurotoxicity 
seen in prion infection.  
Oxidative stress is a known mediator of neurodegeneration and TSE. Unclear is where ROS 
affects the neurotoxic cascade and where they are a major or minor contributor to the 
pathologic damage. Here I could demonstrate significant in vivo protection of antiprion 
mediated toxicity upon the administration of the strong antioxidant AcHyt. Using the same 
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compound we were to demonstrate a modest, but significant increase in survival of prion 
infected mice (Hermann et al., 2015). These data indicate that oxidative stress is not the 
only, but an important signalling pathway that mediates neurotoxicity in prion infection and 
antiprion mediated neurotoxicity. 
NOX2 enzyme is as a major resource of ROS in the antiprion mediated toxicity in vivo. Apart 
from being responsible for the oxidative burst in neutrophils, NOX2 is also expressed in the 
CNS, where it controls key neuronal functions and neuroinflammatory processes (Sorce et 
al., 2012). In neurodegenerative disorders, excessive activation of this oxidase in neurons 
and microglia leads to the production of ROS and oxidative damage (Sorce et al., 2012). 
Further studies revealed an upregulation of NOX2 in prion-inoculated mouse brains and 22L 
prion infected NOX2 deficient mice showed improved motor performance (Sorce et al., 
2014).  
Further, I could confirm specific calpain mediated fodrin cleavage in tissues from mice that 
developed lesions upon antiprion antibody injection. However, neither the inhibitor E64d nor 
the expression of calpastatin had any beneficial therapeutic effect in vivo. This is in-line with 
data from prion-inoculated mice, where both strategies lacked a protective effect (Falsig, 
unpublished). However, this finding is surprising, since inhibition of calpains with E64d have 
been shown to be neuroprotective in prion inoculated slice cultures (Falsig et al., 2012). In 
addition, ROS production has been proposed to be downstream of calpain activation 
(Hermann et al., 2015), thus calpain inhibition should be as protective as ROS inhibition. 
Recently it was proposed that in Aβ1-42 mediated dysregulation of intracellular Ca2+, calpain 
activation led to a protective cleavage of the NCX3 antiporter (Pannaccione et al., 2012). 
Calpains could play a potential Janus-faced role in neurodegenerative disease, mediating 
both protective and pathological pathways. Besides, the differences between in vivo and ex 
vivo systems could simply be related to difficulties in delivering the pharmaceutical 
compound in sufficient amounts to the target region. 
Additionally, we could show that neurotoxicity is caspase independent in both models and 
cannot be abolished with glutamate receptor antagonists or with inhibitors of endoplasmic 
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reticulum channels (Falsig et al., 2012; Hermann et al., 2015). Further convincing evidence 
that both models activate neurotoxic pathways is the demonstration of PERK activation, the 
unfolded protein response and the observation that 80% of transcriptionally downregulated 
genes overlap between both models (Falsig et al., 2012; Hermann et al., 2015).  
 
NCX-3 as a potential source of Ca2+ influx in antiprion mediated neurotoxicity 
Calcium homeostasis is altered in neurodegenerative disease as well as in prion disease. 
After the detection of calpain activation Dr. J. Falsig and Dr. T. Sonati performed an 
extensive pharmacological screening to detect the source of the pathological Ca influx. 
Surprisingly, significant neuroprotection could only be achieved by blocking the reverse 
mode of the NCX-3 antiporter. I could demonstrate that NCX3 deficient mice are nearly 
resistant towards antiprion mediated neurotoxicity. This is suggestive of an early influx of 
calcium into the cytosol. Supporting this observation are additional results that reveal 
neuroprotection based on the antisense oligonucleotide knock down of NCX3 in cerebellar 
slice cultures exposed to POM1 (unpublished Sakata). However, NCX3°/° mice have not 
been shown to be protected upon prion inoculation and in fact became terminally ill prior to 
wt mice. This discrepancy may point to important adaptive changes upon chronic exposure 
to neurotoxic stimuli (Figure 29). Upon prion inoculation cells are exposed to an increasing 
toxic stimulus, in which subtoxic Ca currents in the reverse mode may occur in the beginning. 
This could trigger adaptive changes, in the way that NCX3 is modulated to work in the 
forward mode. The earlier described reduction of bradykinin triggered intracellular calcium 
concentration in prion infected cells, based on the reduction of IP3 second messenger 
(Kristensson et al., 1993; Wong et al., 1996), is potentially a fingerprint of this adaptive 
mechanisms. Indeed, similar adaptive mechanisms have been postulated for Alzheimer 
disease (Pannaccione et al., 2012). The concept in which cells adapt to moderate levels of a 
stressor is called hormesis (Mattson, 2007).  
Further inhibition of the NOX2 enzyme has also been shown to be more protective in the 
antiprion antibody model in vivo than upon inoculation. Also, adaptive mechanisms could 
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either block the generation of ROS via NOX enzymes or the system could adapt to higher 
levels or reactive oxygen species. 
 
Figure 29: Antiprion 
antibodies induce an acute 
form of chronically induced 
prion mediated neurotoxicity 
Neuroprotective pathways can 
not be activated upon 
intracerebral administration of 
neurotoxic antiprion antibodies. 
Thus, neurons die within hours; however, prion titers are increased over days. Neurons will adopt over 
time against the pathologic stressor. However, at a certain point, the prion titer will exceed the capacity 
of the protective machinery of the cell, thus leading to the neurotoxic induction.  
 
Do antiprion antibodies play a role in other pathogenic paradigms? 
Although the tolerance against PrPC is high, in rare cases, toxic antiprion antibodies could 
possibly be generated within the body and lead to autoimmune mediated encephalitis. This 
question is currently being addressed by Dr. med K. Frontzek within our lab, who will perform 
an enzyme linked immunosorbent assay screen searching for the existence of neurotoxic 
antiprion antibodies on the cerebrospinal biobank.  
In addition, the question arises whether the high amount of missfolded prion protein in TSE 
could trigger an immune response in which antiprion antibodies are generated. If so, some of 
these antibodies could possibly trigger neurotoxicity within the brain. This could potentially 
lead to rapidly progressive variants of the disease. Intracerebral inoculated Rag-1 deficient 
cells (Prinz et al., 2003), which lack mature T- and B- cells, showed no increase in survival. 
Thus, under these conditons, antibodies seem to have no impact on the clinical course.  
However, antibodies could play a role in certain forms of prion disease. New variant CJD is 
believed to be an infectious disease due to the oral intake of BSE prions through the 
consumption of contaminated products from cows. One of the hallmarks is that people 
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acquire a rapid form of the disease and die much younger than patients with sporadic CJD. 
In Great Britain, the epidemic peak of patients dying from vCJD was reached in 2000 
(Andrews, 2012), was with only 26 deaths relatively low compared to the population exposed 
to contaminated meat products. However, patients with another genetic profile may show a 
delayed onset of an infectious form of CJD, corresponding to a second peak (Andrews, 
2012). A possible second explanation for the rapid development of the disease mainly in 
young patients could be due to the additional generation of neurotoxic antiprion antibodies. 
The second peak may also result when patients fail acquire pathological antibodies. 
Admittedly, such speculation is not supported by current evidence. However, besides 
screening for pathological antiprion antibodies in young patients, a screen in patients with 
acquired vCJD could be of interest.  
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Outlook 
Which adaptive changes are triggered by PrPSC during amplification? 
While depletion of NCX3 has found to be protective in vivo and ex vivo, in the antiprion 
mediated neurotoxicity, it caused clinical progression in prion-inoculated mice. This 
discrepancy could point to homeotic pathways stabilizing cytoplasmic Ca2+ overload.  
In contrast to stroke, prionopathies are chronic neurodegenerative diseases, in which the 
disease mediator replicates over time. In prion disease, a peak level of prions has to be 
reached before clinical symptoms occur. However, during amplification of PrPSC this 
neurotoxic agent likely triggers adaptive mechanisms.  
With antiprion antibody mediated neurotoxicity, we have for the first time developed an acute 
model system for the chronic disease. This may facilitate discrimination between the initial 
neurotoxic trigger and its adaptive mechanisms.  
In a pilot experiment I thus plan to investigate whether chronic stimulation of toxic Fab 
antibodies can modulate the induction of acute antibodies mediated neurotoxicity.  
 
Depicting the role of the FT functional domains in antiprion mediated 
neurodegeneration 
Our in vivo and ex vivo observations in the antiprion antibody model provide compelling 
evidence that the FT of the prion protein mediates neurotoxicity. In line unstructured or 
flexible proteins are known to be involved in signalling, cell cycle control, protein-protein 
interactions and regulation of transcription and translation (Beland and Roucou, 2012). 
These proteins typically interact with multiple partners, allowing them to switch function and 
display opposite activities (Beland and Roucou, 2012). Accordingly, multiple proteins interact 
with the prion protein; however, do not exclusively bind to the FT (Aguzzi et al., 2008). 
While the binding of copper to the OR promotes the dissociation of PrPC from lipid rafts 
(Taylor et al., 2005), the interaction of the N-terminal polybasic region CC1 with the adaptor 
protein LRP1 (Taylor and Hooper, 2007) results in a rapid and constitutive clathrin-
  63
dependent endocytosis of the prion protein (Sunyach et al., 2003; Taylor et al., 2005). The 
CC1 has further been identified as the major binding site for glycosaminoglycans (GAGs) 
and the binding of heparin to PrPC mediates down regulation of the latter (Pan et al., 2002; 
Warner et al., 2002). Depletion of CC1 in mice has not led to a spontaneous pathologic 
phenotype (Muramoto et al., 1997); however, it has been shown to impair the capacity to 
rescue PrPΔ32-134 induced neurotoxicity (Turnbaugh et al., 2011). Importantly, these mice 
demonstrated a marked increase in survival upon prion inoculation (Turnbaugh et al., 2012).  
It has been suggested that PrPC may play a role in copper metabolism, as OR is known to be 
an efficient copper binder (Hornshaw et al., 1995; Pauly and Harris, 1998). It has been 
proposed that prion protein serves as a recycling receptor for the uptake of copper from the 
extracellular milieu (Pauly and Harris, 1998). An additional copper binding site has been 
reported for the aminoterminus: the residues 96-111, which belong to the CC2 (Jackson et 
al., 2001).  
The neurotoxic phenotype seen in several deletion mutants points to an interaction of CC2 
with the HC triggering these pathologic effects (Aguzzi and Falsig, 2012). The CC2 contains 
an Src homology domain 3 (SH3), which is known to interact with GPI-anchored protein, 
regulate the local concentration of the protein and to activate or inactivate the protein 
function (Lysek and Wuthrich, 2004). 
This finding illustrates that the different domains of the FT have distinct functions and are 
therefore potentially differently involved in prion protein mediated neurotoxicity. The goal of 
my new study is to uncover the role of each functional domain by inserting targeted point 
mutations. In the first round, I produced five different FT mutated prion proteins, with altered 
charges of CC1 and CC2, Cu binding site of the OR, destroyed structure of the OR, altered 
SH3 binding site in CC2 and decreased hydrophobicity of the HC (Figure 30).  
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Figure 30: PrP-mutants projected to be expressed on Prnp°/° slices to assess antiprion 
antibody successibility 
Depicted are the amino terminals of prion protein mutants, from the amino acid 23 to 120. For the 
control, unaltered prion protein (positive control) and the octarepeat depleted mutant (negative control) 
will be expressed. Strategic point mutations will be inserted into the different functional domains of the 
aminoterminus as outlined.   
 
This prion protein mutants are planed to be expressed on Prnp°/° COCS by the use of viral 
vectors (adeno associated virus), before exposure to the neurotoxic F(ab)1POM19. To 
facilitate the read out the constructs will be expressed together with the fluorescent marker 
NeonGreen. Towards this goal I have already cloned two bicistronic constructs using the 
Golden Gate (Cermak et al., 2011) strategy. I used the 2A side of the aphthovirus foot and 
mouse disease polyprotein to induce a co-translational cleavage between the two proteins 
(Donnelly et al., 2001). The first bicistronic design has the NeonGreen in the first and the 
rmPrP at the second position and in the second design the pattern is inverted (Figure 31A). 
In the initial step, I expressed the construct on Prnp°/° ablated Hek cells and found a strong 
expression of NeonGreen for both constructs. After fixation the cells were immunostained for 
PrP using POM1, which revealed simultaneous expression of PrP (Figure 31B). To confirm 
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the important surface expression of PrP, I used a pull-down biotinylation assay, which 
revealed a better surface expression, when the prion protein is in the second position (Figure 
31C).  
 
 
Figure 31: Bicistronic vector design for a simultaneous expression of NeonGreen and PrP 
(A) The bicistronic vector expresses the murine prion protein (rmPrP) before (P-2-N) or after (N-2-P) 
the 2A side. As expression reporter NeonGreen is used. Both proteins are expressed under the control 
of the pCAG-T7 promoter. (B) Expression of constructs on HEK293T cells reveals a strong 
expression of NeonGreen for both constructs. Cells were immunostained against PrP with POM1. The 
prion protein expression from the P-2-N construct differs from the control expression, PrP alone, and 
the expression from N-2-P. Empty refers to a transfection with the original vector used for cloning 
containing neither a NeonGreen nor a PrP cassette. (C) Surface protein got biotinylated before cell 
lysis. Samples got then enriched for surface proteins using Strepta-Avidin beats. 
Immunohistochemical staining on a PrP western blot reveals a stronger surface expression for the P-
2-N construct.  
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PART II 
 
Introduction 
Immunotherapies in TSE  
The clearance of pathological aggregated protein with either active or passive 
immunotherapy is along with the inhibition of its production, the most frequent therapeutic 
strategy in proteinopathies (Aguzzi and O'Connor, 2010). However, reducing the beta 
amyloid burden in Alzheimer diseased patients has to date not been translated into cognitive 
improvement (Wisniewski and Goni, 2014). All the more, the first active immunization Phase 
IIa trial had to be terminated since 6% of vaccinated patients developed aseptic 
meningoencephalitis (Gilman et al., 2005) and in both active and passive immunization 
therapies. Amyloid-related imaging abnormalities occurred (Sperling et al., 2011). Since the 
degree of tau related pathology correlates better with dementia, immunotherapies against the 
intracellular accumulation of tau proteins are currently under investigation (Wisniewski and 
Goni, 2014).  
In 2010 Citron reviews the four models of antibody function in the clearance of pathologic 
protein aggregates. The first model postulates a phagocytic response mediated by microglia. 
In addition, antibodies could possibly remove amyloids based on direct interactions. Another 
model posits that antibodies pull the pathologic protein to the periphery. In the fourth 
proposal, the antibody blocks the toxic effects of the oligomeric pathologic proteins (Citron, 
2010).   
 
Similar to Alzheimer disease, immunotherapy to clear the pathologic protein has been 
assessed in prion disease (Aguzzi and O'Connor, 2010).  In addition to cited mechanisms 
that describe antibody function, antiprion antibodies potentially block the negative effects 
mediated by PrPC, corresponding to receptor blockage.  
As it was difficult initial to produce high affinity antibodies for research purpose based on the 
high host tolerance towards ubiquitously expressed prion protein, active immunotherapeutic 
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strategies in pre-clinical research yield an insignificant increase in survival time upon ip 
inoculation (Magri et al., 2005; Sigurdsson et al., 2003). Thus, passive immunotherapeutic 
strategies are more likely to be successful.  Table 1 summarizes of the following preclinical 
active and passive immunization trial.  
Proof of concept for immunotherapies was established with genetically engineered mice, 
which expressed anti-PrPC antibodies and were protected from extraneuronal prion infection 
(Heppner et al., 2001).  
While passive immunization with antiprion antibodies ICSM18 and ICSM35 (delivered 
intraperitoneally) successfully blocked peripheral RML infection, no effect was seen upon 
intracerebral inoculation (White et al., 2003).  
With intravenous delivery of the antibodies 31C6, 110 and 44B1, a trend towards longer 
survival could be achieved upon intracerebral inoculation of the Chandler or Obihiro strain 
(Ohsawa et al., 2013). Additionally, mini-osmotic pumps have been used to therapeutically 
deliver 31C6, which led in a significant prolongation of intracerebral PrPSC inoculated mice 
(Song et al., 2008).  
Chronic intracerebral administration of the antiprion antibody 4H11, however, resulted in 
severe side effects, consisting of nerve cell loss, gliosis and microglial activation (Lefebvre-
Roque et al., 2007). This toxic side effect resembles the same toxic reaction we and others 
found upon stereotactic injections (Solforosi et al., 2004; Sonati, 2013b). 
These findings raised concerns about the safety of anti-PrPC immunotherapies. However, 
these controversial findings could not be reproduced with D13, ICSM18 or ICSM35, when 
injected intracerebrally at a dose of 2 μg, which led to the conclusion that antiprion antibodies 
do not induce neuronal apoptosis (Klöhn et al., 2012). As demonstrated in the previous part I, 
I could reproduce the toxicity of D13 in tga20, thus this report was surprising. In addition, 
ICSM18 has an overlapping binding epitope with POM1. Thus, the fact that the globular 
ligand ICSM18 appeared innocuous aroused our attention, as it would further extend the 
mapping of the toxic behaviour of GD ligands. This would have been of possible therapeutic 
interest, if the data that ICSM18 is not mediating toxicity could be reproduced.  
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Immunisation Approach Vaccine Effect Reference 
Transgenic expression of 
antiprion antibodies 
6H4 (153-165) Full protection upon 
Intraperitoneal RML 
inoculation 
Heppner et 
al., 2001 
Active immunization with 
PrP peptides 
PrP131-150 
PrP211-250  
Immunogenic response 
and an reduction of PrPRes 
level in tumor transplants 
Souan et al, 
2001 
Active vaccination with 
recombinant mouse prion 
protein 
Full length rec-
PrP 
Increase in the incubation 
period and infection period 
upon intraperitoneal 139A 
inoculation 
Siggurdson 
et al, 2002 
and 2003 
Passive immunization with 
full length antiprion 
antibodies 
ICSM18 (146-
159) 
ICSM35 (91-
110) 
Full protection upon 
intraperitoneal RML 
inoculation 
White et al, 
2003 
Active immunization with 
PrP peptides 
PrP105-128 
PrP119-146 
PrP142-179 
Increased survival in a 
hamster model of TSE 
Magri et al, 
2005 
Passive immunization with 
full length F(ab)1 antiprion 
antibodies delivered with 
mini-osmotic pumps 
4H11  Severe side effects of the 
treatment with neuronal 
cell loss, astrogliosis and 
microglia activation 
Lefebvre-
Roque et al, 
2007 
Passive immunization with 
full length antiprion 
antibodies delivered with 
mini-osmotic pumps 
110 (88-90) 
31C6 (83-89) 
44B1 (143- 149) 
Partly significant 
prolongation of survival 
after intracerebral 
inoculation with the 
Chandler or Obihiro strain  
Song et al, 
2008 
Passive immunization with 
full length antiprion 
antibodies delivered via 
the tail veine 
31C6 (83-89) 
 
Non-significant 
prolongation of survival 
time 
Oshawa et 
al, 2013 
Table 1: Summary of preclinical active or passive immunization trials in TSE 
 
Pharmaceutical safety assessment 
The US Food and Drug Administration considers a safe pharmaceutical drug as one that has 
reasonable risks, compared to the expected benefit and available alternatives (FDA, 1999). 
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This implies that health authorities and regulators have to perform a benefit versus risk 
analysis or a so-called risk assessment of each new pharmaceutical compound. The 
pharmaceutical risk assessment can be divided in four steps: 1. Hazard/Risk identification; 2. 
Determination of the dose-response relationship; 3. Exposure assessment; 4. Integration of 
all data into a final assessment (risk characterization) (RMIT, 2008).  
For the identification of risks of all historical data, theoretical analysis, informed options and 
concerns of stakeholders are included to identify the possible consequences (FDA, 2006). 
After the identification of the hazard, the dose-response relationship is the central concept in 
toxicology (RMIT, 2008). These relationships can either be threshold or non-threshold, the 
latter is used for the majority of non-carcinogenic compounds (RMIT, 2008). For these 
compounds, it is considered that there is a dose or concentration below which the adverse 
effect will not occur. This dose is traditionally addressed with the no-observed adverse effect 
level (NOAL) and the lowest observed adverse effect level (LOAL) (Filipsson et al., 2003). In 
this approach, only data from one applied dose are used, there is alternatively the 
benchmark dose approach, which takes the quantitative dose-response information into 
account (Filipsson et al., 2003).   
Further knowledge about the pharmacokinetics is essential, in particular to estimate the 
concentration of the compound at the target organ (RMIT, 2008). Finally, all available data 
about the compound are integrated in the final risk assessment, which then forms the basis 
for the decision as to whether or not the drug is safe (RMIT, 2008).  
 
Outline of this work 
Passive immunotherapy with antiprion antibodies represents a potential therapeutic strategy 
for TSE. For this approach, a significant pharmaceutical risk has been identified, since some 
of these antibodies potentially mediated neurotoxicity. However, the initial reports about this 
risk have been questioned.  
In part II, I investigated the reasons for the discrepancy in the literature regarding the toxic 
induction of antiprion antibodies upon intracerebral administration. Initially I performed a 
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dose-response analysis of D13 and found the antibody to be toxic at higher concentrations 
than initially reported. I then analyzed the generated data using the benchmark dose 
approach in order to give possible values for safety limits.  
Next, I investigated the neurotoxic potential of the antibody ICSM18, which is an antibody 
under evaluation for clinical use (Klöhn 2012, Klyubin 2014). Here I can demonstrate that this 
antibody has a toxic potential similar to POM1. 
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Results 
Antiprion antibody D13 does induce neurotoxicity  
 
In order to determine the cause of the discrepancies between the reported toxicity of D13, I 
stereotaxically injected the antibody (2 µg in 2 µl PBS) into the left CA1 region of the 
hippocampus of male BL6 mice (A/P: -2 mm, ML: 1.3 mm, DV: -1.4 mm from Bregma), the 
coordinates used from Solferosi and Klöhn (Solferosi 2004, Klöhn, 2012) in the previous 
studies. For control, antibodies pre-incubated with a three-fold molar excess of a 
recombinant murine PrP fragment encompassing residues 90-231 (rmPrP90-230), were 
injected into the right hippocampus. Histological examination at 48h pi and DWI 24h pi failed 
to reveal lesion induction other than needle tract damage (Fig. 32A – C upper row). 
Since bioactivity between antibody batches and the assessment of protein concentration can 
vary between labs and methodology, I examined the toxicity of D13 at increasing antibody 
doses. A significant hyperintense lesion was recorded on DWI 48h pi of 6 µg and 12 µg D13 
in the hippocampus and/or cortex of 4 out of 5 mice, respectively (Fig. 32A, middle and lower 
row), whereas there was no signal alteration on the side exposed to blocked antibody. 
Histologically, D13 (48h pi) caused conspicuous edema and widespread acute neuronal 
damage affecting large cortical and/or hippocampal areas (Fig. 32B-C, middle and lower 
row). Affected neurons displayed condensed hyperchromatic nuclei and hypereosinophilic 
cytoplasm (Fig. 32C, middle and lower). Some neurons showed prominent nuclear 
fragmentation. 
Solferosi could show positive labelling performing terminal deoxynucleotidyl transferase 
dUTP nick end labelling (TUNEL) indicative for apoptosis. Therefore, I performed TUNEL 
staining on all sections and found positive cells in lesions of mice injected with 6 µg and 12 
µg D13 but not in 0 µg (Fig. 32D). In contrast, activated caspase-3 (aC3) 
immunohistochemistry labelled only few cells (Fig. 32E). This result is in line with data from 
slice cultures experiment, where antibody mediated neurotoxicity has been described to be 
independent of caspase activation. 
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I then quantified lesion size based on a DWI dataset as previously described and blotted a 
dose response curve. From this blot I determined that the lowest observed adverse effect 
level (LOAL) is 10 μM / 6 μg. Using specialized software, I then calculated the benchmark 
dose level as 5.2 μM / 3.1 μg (Figure 32 F). 
Figure 32: Dose-response analysis of acute D13 triggered neurotoxicity.  
(A) DWI at 48h after injection of D13 (2, 6 and 12 µg; respectively, 6.6, 20 and 40 µM) into the left 
hippocampus. For a control, D13 was preincubated with a three-fold molar excess of rmPrP90-230 
(+rmPrP) and injected into the right hippocampus. Whereas both D13 and D13 +rmPrP induced 
superficial injection-related lesions, only D13 induced extensive hyperintensity throughout the 
hippocampus. (B) Haematoxylin and eosin (H&E) stained sections from the mice shown in (A) 
(asterisks: needle tracts; rectangles: regions magnified in (C). Incisions were introduced as post-
mortem landmarks). (C) Higher magnification of Cornu ammonis, sector 1 (CA1, left panel with blue 
border: D13 injections at 2, 6 and 12 µg, right panel with black border: D13 +rmPrP) showing vacuoles 
indicative of edema (arrowhead) as well as numerous neurons with condensed chromatin, 
hypereosinophilic cytoplasm (asterisks), and nuclear disintegration (arrow). At 12 µg the tissue is 
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looser indicative of more advanced lesion formation. (D) TUNEL stained paraffin sections of the CA1 
region of the mouse injected with 6 µg shown in (A-C). Quantitation showed 41 ± 19% TUNEL+ cells 
(n=30 fields at 20x) after exposure to D13 and ca. 0.5% TUNEL+ cells on the contralateral side 
exposed to D13+recPrP. Blue: nuclear counterstaining with 4’,6-diamidino-2-phenylindole (Dapi). (E) 
Confocal laser scanning microscopy of paraffin sections immunostained for activated caspase-3 
revealed sparse positive cells (white arrowhead) after injection of 6 µg D13. (F) Fit of the dose 
response curve modelling an S-shaped dose-response relation (Y[dose] = intercept + v*dose^n/(k^n + 
dose^n); software BMDS 2.4, U. S. EPA). The benchmark response (BMR, green line) is determined 
as a 5% increase of lesion volume over control injections (mean of lesion induction upon blocked D13 
injection: 0.056 mm3). The Benchmark Dose (BMD, blue line) corresponds to the BMR and was found 
to be 5.2 μM / 3.12 μg. The violet line indicates the lower confidence interval that results in the 
benchmark Dose Level (BMDL) calculated as 3.9 μM / 2.3 μg. The with arrow represents the no-
observed-adverse effect level (NOAEL: 3.35 μM / 2 μg) and the black arrow, the lowest-observed-
adverse effect level (LOAEL: 10 μM / 6 μg).  
 
ICSM18 triggers mouse hippocampal neurotoxicity  
Next I was interested in addressing the toxic potential of ICSM18 at 6 µg upon injection into 
the left CA1 region of the hippocampus. In order to exclude sex and strain issues, I used 
female BL10 mice, which are matched with respect to the Klöhn study of. As performed in 
the study by Klöhn, I administered IgG1 isotype control (BRIC222, American Research 
Products, 6 μg) into the contralateral position as well as ICSM18 (6 μg) into prnp°/° mice. 
DWI depicted a small lesion 24h pi in one out of five mice, which was not seen in the control 
group (Fig 33A). Serial H&E stained sections (48h pi) revealed a lesion comparable to the 
D13 injection and distinct from the lesion tract damage (Fig 33A-B). Statistical analysis of the 
volumetric quantification yielded no significant differences between ICSM18 injection into 
wild type mice compared to injection into Prnp°/° mice and isotype control injection (Fig 33C; 
p=0.6427). 
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Figure 33: ICSM18 trigger mouse hippocampal neurotoxicity.  
(A) A 0.2 mm3 hyperintense lesion (arrowhead) was found upon DWI 24h pi of 6 µg ICSM18 into the 
left CA1 region (inlay: illustration of stereotactic coordinates) in one BL10 mice. No such signal 
alteration was found on the contralateral side injected with BRIC222 as IgG1 isotype control. Right 
side, corresponding H&E section 48h pi (asterisks: needle tracts; rectangles: regions magnified in (B)). 
(B) High magnification image (red border) at the position where the hyperintensity was recorded 
shows neurons with condensed nuclei and hypereosinophilic cytoplasm (asterisks). The mechanical 
lesion induced by the needle tract is characterized by cellular debris (white arrowhead). (C) 
Quantitative analysis of lesion volume from DWI images shows no significant lesion induction at 6 µg 
ICSM18 when the antibody is injected into CA1 (inlay: illustration of stereotactic coordinates; one-way 
Anova with Tukey’s post test, n(Prnp°/°)=4, n(BL10)=10).  
 
By inducing neurotoxicity in the hippocampus by POM1, I found that injection into the CA3 
region yields more robust results. I therefore administered the antibodies into the 
hippocampus with previously used coordinates (A/P: -2 mm, ML: 1.3 mm, DV: -1.4 mm from 
Bregma). Hyperintense lesions were found in three out of four BL10 mice (Fig 34A, E), which 
were subsequently confirmed by histological analysis (Fig 34A, B). Lesion volumes differed 
significantly between ICSM18 and control injections (Fig 34D-E; p=0.0062). No lesions were 
found upon injection of 2 μg ICSM18 (Fig 34C, E). In order to test for gender and / or strain 
mediated differences I additionally injected 6 μg ICSM18 from the same batch into BL6 male 
and female and found an increased negative effect in BL6 female in contrast to BL10; 
however, the difference between gender and strain is not significant (Fig 34E). Quantitative 
analysis reveals that there is no significant difference between the negative effects of 
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ICSM18 in comparison with POM1 (Fig 34E). As expected, lesion induction of ICSM18 is 
PrPC expression dependent (Fig 34E).  
 
Figure 34:  ICSM-18 at CA1 
(A) Representative DWI 24h after stereotactic injections of 6 µg ICSM18 versus BRIC222 into the CA3 
(inlay: illustration of stereotactic coordinates) region of a BL10 mouse. The arrowhead points to a 0.4 
mm3 hyperintense lesion. Right side corresponding H&E section 48h pi (asterisks: needle tracts; 
rectangles: regions magnified in (D)). (B) On higher magnification next to healthy neurons, numerous 
undergoing cell death (asterix) are seen in the dentate gyrus upon injection of 6 µg ICSM18 (red 
border), although not seen upon 6 µg BRIC222 injection (blue border). (C) Representative H&E 
images at high and low resolution 48h pi of 2 µg ICSM18 versus 2 µg BRICC222. No lesions are 
found. (D) No lesions are found at 48h pi of 6 µg ICSM18 into the CA3 region of Prnp°/° mice. (E) 
Significant lesion induction is found upon injection of ICSM18 into the CA3 region of BL10 male and 
BL6 female and male. A 6 fold increased lesion is found in tga20 males in contrast to BL6 females. 
Analysis of the stereotactic injection of POM1 at the same dose reveals a comparable negative effect 
to the injection of ICSM18 in BL6 mice. (inlay: illustration of stereotactic coordinates; Multi column 
comparison with (first four samples) one-way Anova with Tukey’s post-hoc test; comparing of two 
samples with two-tailed Student’s t-test, n  =4, ***P<0.001, **P<0.01, *P<0.05, ns: not significant.). 
Distribution of holoantibodies upon stereotactic injection 
In order to obtain more information about the tissue exposed upon intracerebral 
administration of antiprion antibodies, I next addministered labeled Cy5-POM2 antibody at 2 
and 6 µg into the CA1 region (Fig 35 A). On Cryo-sections 24h post injection, I found that 
labeled holoantibody is distribution to a volume of 1.8 mm3 for 2 µg and to a 5 mm3 for 6 µg 
(Fig 35B).   
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Figure 35: The distribution of an antibody in the brain is concentration dependent 
(A) Representative Cryo-sections 24h post injection of 2 µg and 6 µg Cy5-POM2 into the CA3 region. 
(B) A mean volume of 1.8 mm3 was found upon administration of 2 µg and a volume of 5 mm3 upon 6 
µg Cy5-POM2. The difference was not significant (n =3, Student t-test).  
 
With this additional data, I calculated the relation between lesion volumes to antibody 
distribution and found that ICSM18 affects 84% of injected volume in tga20 male mice and 
5.2% in BL10 female mice (Table 2).  
 
 D13   ICSM‐18   
 CA1   CA1 CA3 CA3 CA3 CA3 CA3
Dose 2 6 12 6 2 6 6  6  6
Conc 6.6 20 40 20 6.6 20 20  20  20
Animals 5 5 5 5 3 4 4  4  3
Strain BL6 BL6 BL6 BL10 BL10 BL10 BL6  BL6  tga20
Sex  m  m  m  f  f  f  m  f  m 
Lesion  0 4 4 0 0 3 4  4  3
Lesion volume 
(mean ± SD)  
0.03± 
0.02 
3.54± 
3.16 
11.34± 
15.28 
0.09±
0.09 
0.04±
0.04 
0.26 ± 
0.15 
0.41± 
0.17 
0.65±
0.59 
4.2±
2.5 
Lesion/AB 
Distribution (%) 
1.6  70.8  ‐  1.8  2.2  5.2  8.2  16.2  84 
Table 2: Summary of data generated in the risk assessment  
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Chronic exposure to toxic antiprion antibodies 
A stereotactic intracerebral administration of a singel dose of antiprion antibodies is not the 
likely way used for clinical administration. Therefore, in a collaboration with Uli Hermann, we 
chronically administrated the Fab fragment of the highly toxic antibody POM1 (75 µg via 
Alzet pump, 0.25 µl/h, 0.6 µg/µl, 21 days, tga20 mice), which has a comparable neurotoxic 
effect as ICSM18, and induced 4 days after pump implantation a hyperintense lesion around 
the implanted canula not seen in prnp°/° mice (echo planar imaging, Fig 36A). The 
hyperintense signal disappeared 11 days post implantation (Fig 36B). MEMRI and H&E 21 
days post implantation proved lesion induction (Fig 36C-D). Upon volumetric quantification 
based on the MEMRI image 9% ± 3% of the brain volume (Prnp°/° 1% ± 0%) was found to be 
damaged. 
 
Figure 36: Chronic delivery of the Fab fragment via mini-osmotic Alzet pumps 
(A) Representative DWI 4 days post implantation of a mini-osmotic Alzet pump delivering the Fab 
fragment of POM1. A large hyperintense lesion was recorded in tga20 mice, not seen in Prnp°/° mice. 
(B) Images of the same mice 11 dpi. The hyperintese signal disappeared. (C) Coronal MEMRI images 
of the same animals as shown in A and B. Extensive damage of the tga20 brain architecture was 
mainly located in the left hippocampus. (D) Representative H&E sections 21 dpi from the same mice 
as shown in A-C confirming lesion development in tga20 mice.  
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Discussion 
Risk characterization of toxic antiprion antibodies 
Klöhn et al. concluded that "PrP antibodies do not trigger mouse hippocampal neuron 
apoptosis" (Klöhn et al., 2012). However, my results indicate that this conclusion is incorrect 
and that both ICSM18 and D13 are neurotoxic. I could reproduce the initial reported 
neurotoxicity of D13 used from Klöhn et al. as a positive control, at a threefold higher 
concentration than initially reported. Since it is not possible to assess the concentration or 
bioactivity of the initial antibody batches used in previous studies, I can only speculate about 
the dosage discrepancy. Here I show that variation of the injection coordinate can influence 
the volume of lesion induction and I provide further evidence for other variables that possibly 
influence these experiments. In my view, there is either a difference between labs in the 
bioactivity of antibody batches or the methods to determine of the concentration. 
Neurotoxicity has therefore been identified as a potential hazard of antiprion antibodies by 
different laboratories (Tabel 3). 
 
Most likely, the first patients envisaged for clinical studies will be those suffering from 
sporadic CJD (sCJD), as this is the most frequent prion disease in humans. sCJD is 
hypothesized to begin with a spontaneous change of the prion protein within the brain. 
Accordingly, pre-clinical studies are required to prove efficacy upon intracerebral inoculation. 
However, a cumulative dose of 8 mg of ICSM18 (injection of 2 mg intraperitoneal twice 
weekly) has been shown to be ineffective upon intracerebral inoculation (White et al., 2003). 
Most likely, the antibody passes through the blood brain barrier in sufficient amounts only 
during the terminal stages of the disease, as it has been shown for 31C6 (Ohsawa et al., 
2013). Thus, an intracerebroventricular route of administration should be selected. The only 
published study on delivering anti-prion antibody via this route (31C6) used 336 µg (0.5 µl/h, 
14 days, 2 mg/ml) to achieve a significant but small prolongation of survival in prion 
inoculated mice (Song et al., 2008). 
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The lack of preclinical data on the efficacy and toxicity of ICSM18 for the treatment of sCJD 
mandates caution with respect to the use of anti-prion antibodies in clinical studies. 
 
Steps ICSM18 
Hazard identification Induction of acute neurotoxicity  
(Lefebvre-Roque et al., 2007; Solforosi et 
al., 2004; Sonati, 2013b) 
Determination of the doses-response 
relationship 
D13: BMDL 3.9 μM / 2.3 μg , NOAEL: 3.35 
μM / 2 μg, LOAEL:  10 μM / 6 μg 
ICSM18: NOAEL : 3.35 μM / 2 μg, LOAEL: 
10 μM / 6 μg 
Exposure assessment (Ohsawa et al., 2013) 
Integration of all data into a final 
assessment; risk characterization 
Preliminary 
Table 3: Summary of risk assessment for ICSM18.  
 
Alternative ligands for the treatment of TSE 
Despite the described neurotoxic risk of antiprion antibodies for the treatment of CJD, 
passive immunotherapies still represent a promising treatment strategy.  
As demonstrated, not all ligands that bind PrPC induce neurotoxicity. Thus, one of the 
strategies assessed Dr. S. Senatore in our lab by aims to discover rare non-
immunodominant epitopes. This will be achieved by phage display coupled with next 
generation sequencing.   
In a second strategy, Dr. T. Sonati aims to investigate small molecules that target PrPC, in 
order to identify POM1 / POM2 competitors. 
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CONCLUDING REMARKS 
 
Here I demonstrate that MRI based quantification can be used as an early and precise 
surrogate marker of anti-prion mediated neurotoxicity in vivo. One may question the impact 
of this new assay on prion research.  
In patients MRI examination belongs to the routine clinical evaluation for the pre-mortem 
diagnosis of sCJD (Zerr et al., 2009). There is compelling evidence that positive signal 
alterations are found early in the disease (Shiga et al., 2004) and patients with other 
proteinopathies rarely show positive results (Zerr et al., 2009). MRI offers a high resolution, 
noninvasive method to identify subtle changes in brain structure, and therefore represents a 
powerful clinical and research tool for many neurological disorders.  
The pre-clinical gold standard for a promising new TSE pharmaceutical agent is a significant 
prolongation of survival time of inoculated animals in vivo. This assay allows precise 
quantification, given the stereotypical fatal clinical phase (Sandberg et al., 2011). However, 
other positive effects of a drug such as a delay of symptoms or neurodegeneration are by 
default not assessed. Functional testing like rotarod test has recently been used (Sorce et 
al., 2014) to gain more information about disease progression. Additional examinations like 
cerebrospinal fluid biomarkers, electrophysiology and MRI are rarely used in animal models 
of prion disease. For the most part, biosafety issues hamper the implementation of these 
methods.  
In contrast, research based on the antiprion mediated neurotoxicity model can be performed 
at biosafety level one. We could demonstrate that this model shares many similarities with 
neurotoxicity found in prion infection (Hermann et al., 2015; Sonati, 2013b). Therefore my 
established assay can be used for rapid assessment of the neuroprotective potential of 
compounds in vivo.  Sequential imaging at different time points is possible and allows 
investigation of delayed neurodegeneration. Furthermore, the model facilitates in vivo 
investigation of the dose and route of administration prior to the more complex inoculation 
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studies. In addition, the burden of experimental animals in this assay is significantly lower, 
since the neurotoxic effect is restricted to a limited area of the brain.  
The acute nature of the model offers an advantage for the investigator and reduces the 
burden of animals in the experiment. However, the discrepancy in results between models 
for NCX3 deficient mice illustrates that the new assay lacks the power to fully replace 
inoculation experiments. The promising results based on the in vivo anti-prion model still 
need to be confirmed in an inoculation experiment. It should be pointed out that differences 
in results are hypothetically of similar importance than equal results between the models, as 
they potentially uncover important adaptive changes in the chronic inoculation model. 
Passive immunotherapy in order to stop or delay disease progression in TSE continues to be 
pursued as a therapeutic strategy. Our results as well as others have described fatal 
neurodegenerative side effects of some antiprion antibodies (Lefebvre-Roque et al., 2007; 
Solforosi et al., 2004; Sonati, 2013b). Although the relevance of these effects in humans is 
unclear and intracerebral application will not be used, it is conterintuitive to take the financial 
risk of a clinical study with a compound that has already demonstrated neurotoxicity in pre-
clinical study. Here I appeal to the prion research community to initially invest in novel prion 
protein ligands, which will then be rigorously tested for their neurotoxic potential. I propose 
that identification of a hyperintese signal on DWI will be used as a risk assessment tool in 
further in vivo safety studies. I have found the relationship between a histological lesion and 
a positive signal on DWI to be excellent. In contrast to conventional histological methods, the 
whole brain is assessed in a single MRI session, without the risk of tissue loss upon 
sectioning. As more sequential imaging at different time points in intact mice is possible, the 
method promises to approximate the clinical setting. In fact, as animal MRI becomes more 
widely available, the feasibility of my proposal is increased. 
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MATERIAL AND METHODS 
 
Mice 
All mouse experiments were performed according to Swiss federal regulations and were 
approved by the Animal Experimentation Committee of the Canton of Zurich (permits 
200/2007, #41/2012). Mice were housed under specific pathogen free conditions.  
Female and male inbred mouse strains C57BL/6JOlaHsd1 (BL6), C57BL/6J (BL6J) and 
129S2/SvHsd (129) were bred in-house. C57BL/6NHsd2 (BL6/Hsd2) and C57BL/10 (BL10) 
were purchased from the Harlan or Jackson laboratory, respectively. Coisogenic BL6.129-
Prnpo/o, BL6.129-Prnpo/o-tga20+/+ (tga20), BL6.129-Prnpo/o-C4/C4 (PrP∆32-93), BL6.129-Prnpo/o-
Prnpo/o-L52 (PrP∆94-110), BL6.129-Prnpo/o-NSE-PrP+/+ (NSE-PrP) and mice were on a mixed 
129S2/SvHsd and C57BL/6JOlaHsd1 background (Brandner et al., 1996; Bremer et al., 
2010; Büeler et al., 1992; Fischer et al., 1996; Flechsig et al., 2000; Radovanovic et al., 
2005). Congenic Edinburgh 129-Prnp-/- were on a pure 129S2/SvHsd background (Manson et 
al., 1994).  
Coisogenic BL6J.129-Cybbtm1Din/J (NOX2°/°)-deficient mice were generated on a mixed 
129S2/SvHsd and C57BL/6JOlaHsd1 background and backcrossed to C57BL/6J (Pollock et 
al., 1995). Coisogenic heteroczygous BL6J.FVBN-hCast+/- (Rao et al., 2008) were crossed 
with BL6.129-Prnpo/o-tga20+/+ (tga20) to generate Prnpo/o-hCast+/--tga20+/- (hCast+/--tga20+/-) 
and Prnpo/o-hCast-/--tga20+/- littermates (hCast-/--tga20-/+). Coisogenic 129.CD1-NCX3 
deficient mice were generated on a mixed 129Sv/CD1 background (Sokolow et al., 2004) 
and were crossed with a C57BL/6JOlaHsd1 mouse to generate NCX3+/+ and NCX3-/- 
littermates in the second generation.  
 
Chemicals and the generation of antibody derivatives and recombinant PrP 
All compounds were purchased from Sigma/Aldrich unless otherwise stated.  
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POM monoclonals (Polymenidou et al., 2008) and D13 (Williamson et al., 1998) were 
produced in-house based on hybridoma technology and purified by affinity chromatography 
using protein G sepharose. A purity of around 90% was achieved for the monoclonals as 
analyzed by with silver stained SDS-PAGE. The monoclonal ICSM-18 was a generous gift 
from Simon Hawek and was dialyzed against PBS prior to intracerbral injection.  
F(ab)1 POM fragments were generated in house from the POM antibodies using papain 
digestion and purification with Protein A agarose followed by size exclusion chromatography. 
ScFvPOM1 and ScFvPOM2 were generated in the Zürich laboratory of Neuropathology by 
expression in E. coli and purification from insoluble inclusion bodies as previously described 
(Polymenidou et al., 2008). Recombinant mouse PrP was generated in E. coli and purified by 
high-affinity column refolding (Zahn et al., 1997). 
 
Volumetric phantoms  
Small cubes or irregular shaped bodies with a calibre between 1 and 10 mm were generated 
from the polymer clay FIMO® (Staedtler). In order to estimate density, three additional 
cylinders with a side length between 1 to 3 cm and a calibre of 9 mm were prepared. The 
material was then solidified in the oven at 110 °C for 30 minutes. Subsequently, all bodies 
were weighed with an analytic balance. The larger cubes were placed in a 10 ml cylinder 
half-filled with water. The volume was estimated based on the displacement of the water. 
Based on the volumes and weights, the mean of the density of the solidified polymer clay 
was estimated. By dividing the weight with the density the volume of the smaller bodies was 
calculated.  
Each of the bodies was then placed into 5% Agarose (NuSieve low melting Agarose FMC 
BioProducts) into a 10 ml tube. Volume phantoms were placed into a 4.7-Tesla Bruker 
Pharmascan with a special 10 ml tube holder (Bruker). Images were acquired with the same 
sequence as used for MEMRI as described in the following chapter.  
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MEMRI and DWI 
For MEMRI, mice received five intraperitoneal injections of MnCl2 (40 mgkg-1, 20 mM in H2O 
and bicine, pH 7.4) at 12h intervals (Grunecker et al., 2010). The final injection was 
administered immediately after the stereotaxic injection.  
For imaging acquisition, the mice were placed under isoflurane anesthesia at 4h, 24h and 
72h post-surgery. Initially, the mice were placed on a bed equipped with a mouse whole-
body radio frequency transmitter coil and a mouse head surface-coil receiver and then into 
the 4.7 Bruker Pharma scan. Body temperature was maintained with a warming blanket.  
For MEMRI T-1 weighted brain images were obtained using a 3D gradient-echo sequence 
with the following parameters: TR: 15 ms, TE: 2.5 ms, flip angle: 20 deg, Average: 10, Matrix: 
265/265/126 Voxel, Field of View: 2x2.56x2 cm3, Acquisition time: 1 h, Voxel size: 
78x100x156 μm3. For DWI, routine gradient echo sequences with the following parameters 
were used: TR: 300 ms TE: 28 ms, flip angle: 90 deg, Average: 1, Matrix: 350 x 350, Field of 
View: 3 x 3 cm, Acquisition time: 17 min, Voxel size: 87x87 μm3, slice thickness: 700 μm3, 
Isodistance: 1400 μm3 and b values: 13, 816 s/mm2. For chronic treatment diffusion weighted 
images were achieved with an echo planar sequence with: TR: 7500, TE: 44.6, Voxel size: 
0.1x0.1x0.7 mm, b value: 500 s/mm2.  
 
Quantification of MRI scans 
Quantification was performed with ParaVision software (Version 5,Opl3,Bruker). Lesions 
were quantified by assessing two regions of interest (ROIs), corresponding to the lesion and 
total cerebellar or hypocampal area. ROIs were set for each optical slice of the data set. For 
the quantification of hippocampal lesions with MEMRI scans, the volume of non-affected CA3 
was measured. ROIs were set on the ipsilateral and contralateral sides of injection. Volumes 
for each ROI were calculated by multiplying the sum of the ROI area by the voxel height. 
Data are presented as the lesion volume divided by the total cerebellar volume or 
hippocampal volume. For hippocampal lesion of MEMRI scans data are presented as CA3 
volume (mm3), separated by ipsilateral versus the contralateral side. 
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Volume phantoms were additionally analyzed with the Myriam (Intrasense) software. ROIs 
were set to the corresponding area of the imaged bodies.  
For the statistical analysis of experiments involving the comparison of three or more data 
sets, we used one-way ANOVA with Dunnett’s post-hoc test for comparison of all data sets. 
One or two-tailed unpaired Student’s t-test was used to compare two data sets. The results 
are displayed as mean ±s.d. *P,0.05; **P,0.01; ***P,0.001, ****P,0.0001. 
 
Stereotactic injections 
Mice were anaesthetized with isoflurane and placed in a motorized stereotaxic frame 
controlled by software with a three-dimensional brain map, allowing for real-time monitoring 
of needle placement (Neurostar). The skull was exposed by a midline incision and a small 
hole was drilled using a surgical drill. The needle (Hamilton, pstAS, gauges 26 s) was then 
mounted in an electronic micro-injector unit and was placed for cerebellar injection at the 
following lambda coordinates: AP -2.3 mm, ML 0 mm, DV 2 mm, for CA1 injection at: A/P: -2 
mm, ML: 1.3 mm, DV: -1.4 mm from Bregma or for CA3 injection at the following bregma 
coordinates: AP – 2 mm, ML ±1.7 mm, DV 2.2 mm, angle in ML/DV plane 15°. Antibodies (2 
μl) were injected at a flow-rate of 0.5 μl/min and the needle was left in place for 3 min. The 
mice were sutured and then received an injection of buprenorphinum (0.1 mg per g of body 
weight). 
 
Hematoxylin Eosin staining and immunohistochemistry of formalin-fixed, paraffin 
embedded tissue 
Mice were euthanized after the last scan (5, 24 or 72h post injection) and the brains were 
fixed in 4% formalin. Cerebella or a 4mm coronal section from the posterior cortex were 
paraffin embedded and 2 μm coronal step sections (standard every 100 μm) were cut, 
deparaffinized and routinely stained with hematoxylin and eosin.  
For immunohistochemistry, sections were deparaffinized through xylol and graded alcohols. 
Then heat-induced epitope retrieval in the microwave was performed in 10 mM citrate buffer 
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at pH 6. Sections were then incubated for 1h in blocking buffer (0.2% Triton X-100, 10% 
normal goat serum dissolved in phosphate-buffered saline: PBS) and incubated with 
unconjugated rabbit monoclonal anti-NeuN (10 μg ml-1, Millipore) or rabbit polyclonal anti-
Caspase3 (5 μg ml-1, Milipore) diluted in blocking buffer at 4 °C over night.  
After washing with PBS, sections for 3,3′-Diaminobenzidine tetrahydrochloride hydrate (DAB) 
immunohistochemistry, were then incubated for 1 hour at room temperature with the specific 
biotinylated secondary antibody (10 μg ml-1, Vector Laboratories). This step was followed by 
several washes with PBS and incubation in horseradish peroxidase-avidin/biotin complex 
solution (Vector Laboratories). For visualization sections were incubated for 5 minutes in 
DAB (0.5 mg/ml) dissolved in phosphate buffer (0.1 M, pH 7.4) and then DAB conversion into 
a insoluble brown product was induced with hydrogen peroxide (H2O2).  
For indirect immunofluorescence detection, brain sections were incubated with specific 
fluorescent-labeled secondary antibody (1 μg ml-1 Alexa Fluor 488). In the final PBS wash 
4,6-diamidino-2-phenylindole, dihydrochloride (DAPI; Molecular Probes) was added and 
sections were mounted with Fluor Save (Calbiochem). For analysis, pictures were taken with 
a FluoView® FV10i Confocal Laser Scanning System. 
 
TUNEL stainings 
During apoptotic cell death, DNA is fragmented by endonuclease activity. Free hydroxyl 
groups at the 3’end can be labeled by the enzyme Terminal deoxynucleotidyl transferase 
(TdT) with labeled nucleotides, a method known as Terminal Uridine Deoxynucleotidyl 
Transferase dUTP nick end labeling (TUNEL) staining. The in situ Cell Death Detection kit 
(Roche) was used according to the manufacturer’s instructions. In brief, two micrometer 
sections of paraffin-embedded brain tissue were deparaffinized, rehydrated and incubated 
with proteinase K (PK) 20 μg ml-1  for 10 min at 37 °C to break through the formalin fixation 
induced protein cross links. Then the sections were incubated with the working-strength 
terminal deoxynucleotidyl transferase (TdT) enzyme and digoxigenin labeled dUTP for 60 
min at 37 °C, following staining with fluorescently labeled anti-digoxigenin antibody. Sections 
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were counterstained with DAPI. 
 
Pharmacological treatment of animals  
For acetylated hydroxytyrosol (Granados-Principal et al., 2010), mice were treated starting 7 
days before injection with 2 g l-1 in the drinking water.  
The calpain inhibitor E64D (Mehdi, 1991) was injected intraperitoneally at 5 mg/KG 30 
minutes before and 4 hours post stereotactic antibody injection.  
 
Inoculation of mice 
Three-month-s old mice were inoculated intracerebrally into the left hemisphere with 30 μl of 
Rocky Mountain Labaratory strain mouse-adapted scrapie prions passage-6 (RML-6) at a 
concentration of 0.1% homogenate, corresponding to 3 x 105 LD50. Prior to the expected 
beginning of symptoms, mice were monitored every second day. After the onset of the 
characteristic clinical symptoms (ataxia, kyphosis, tail rigidity and hind leg paralysis), the 
mice were monitored daily. At the terminal stage of the disease, the mice were sacrificed.  
 
Fodrin Western blot 
The mice were euthanized after the 24h scan and the cerebellum or dissected hipocampus 
was snap frozen with liquid nitrogen. The extracted tissue was homogenized in PBS with 
0.32 sucrose supplemented with complete mini protease-inhibitor mix (Roche)and 
homogenized by trituration using a 30 G syringe. The protein concentration was determined 
using the bicinchoninic acid assay (Pierce). Samples were prepared in loading buffer 
(NuPAGE, Invitrogen) and boiled at 95 °C for 5 min Proteins (10 μg per lane) were separated 
on a 4–12% gradient gel (NuPAGE, Invitrogen) and blotted onto a nitrocellulose membrane. 
Membranes were blocked with 5% w/vol Topblock (Fluka) in Tris-buffered saline 
supplemented with Tween (150 mM NaCl, 10 mM Tris HCl, 0.05% Tween 20 (vol/vol)) and 
incubated with primary mouse anti-α-fodrin (AA6, 100 ng ml-1, Millipore) and mouse anti-actin 
(100 ng ml-1, Chemicon) in 1% Topblock overnight. After washing in Tris-buffer, the 
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membrane was incubated with horseradish peroxidase (HRP)-conjugated rabbit anti–mouse 
IgG1 (1:10,000, Zymed) for an hour. Finally blots were developed using SuperSignal West 
Pico chemiluminescent substrate (Pierce) and visualized using the VersaDoc system (model 
3000, Bio-Rad).  
 
Detection of antibody distribution with Cy5 labeled POM2  
The entire antibody POM2 was labeled with using the Cy5 mAB labeling kit (GE Healthcare 
Amersham) and injected into the hippocampus of 3-month-old mice. Twenty-four hours post-
antibody injection, the mice were euthanized and 4 mm coronal sections of the posterior 
cortex were embedded in Hanks balanced salt solution and frozen with liquid nitrogen. 
Cryosections (10 μm thick) were prepared and stained with DAPI (Molecular Probes) and 
mounted with Fluor Save (Calbiochem). Sections were then imaged with the virtual 
microscope Axio Scan Z1 (Zeiss).  
 
Mini-osmotic pump implantation 
Mini-Osmotic Pumps (Alzet Model 2004 0.25 µl/h) were filled with antibody diluted in PBS, 
according to the manufacture’s instructions. Filled pumps were placed in PBS at 37 °C for 
24h. Tga20 was anaesthetized with isoflurane and placed in a motorized stereotaxic frame 
as described above. Next, the skull was exposed via an incision along the midline. Using 
blunt surgical dissection, a paraspinal, subcutaneous pouch was generated, in which the 
pump was positioned. A MRI compatible polyetheretherketone medical microtubing (Alzet) 
was connected to the pump and positioned at the following bregma coordinates: AP -0.22 
mm, ML 0.9 mm, DV 2.5 mm and fixed to the skull with glue (AdheSe One F Viva Pen Refill 
and Heraeus Kulzer FLOWline). Mice were housed individually after surgery. Post 
intervention, the mice were treated with subcutaneous injections of Temgesic® (0.1 mg/kg), 
Finadyne® (5 mg/kg) and Glucose 5% (20 μl/kg). Borgal® (2 ml of 24%) and sugar (30 g) 
were added per liter of drinking water for one week post-surgery.   
 
  89
Golden Gate cloning of Bicistronic Vectors 
Both bicistronic vectors were assembled using Golden Gate cloning (Engler et al., 2008). 
The method is based on IIs restriction endonucleases, which cleave the DNA outside their 
recognition sequence, such as Esp3I (Thermo Scientific). This enzyme recognizes CGTCTC 
sites and generates one base pair downstream the four base pair overhang.  
The pCAG-T7 destination vector is based on the plasmid pCAG-RebZFN-L (a generous gift 
from Pawel Pelczar) and contains a LacZ cassette flanked by two Esp3I recognition sides 
and an Ampicillin resistance cassette. By digestion with Esp3I of the pCAG-T7 destination 
vector, the LacZ cassette was excised and a 3’GTGG overhang downstream of the CAG/T7 
promoter and a 5’GTCA overhang upstream of the polyadenlyation signal were generated.  
For the generation of the pCAG-T7-NeonGreen-2A-mPrP construct, two inserts for golden 
gate cloning into pCAG-T7 destination were generated by PCR. The first insert contained 
NeonGreen (Shaner et al., 2013) and the N-terminal (aa 1-28) part of the 2A side, the 
second insert the C-terminal (aa 29-67) component of the 2A side and the normal murine 
PrP. For generating the pCAG-T7-PrP-2A-NeonGreen, the reversed design was used. 
Primers (all purchased from Mycrosynth) were designed so that the Esp3I digestion of the 
PCR products generated a 5’ CACC overhang on the first insert and a 3’ CAGT overhang on 
the second insert, comparable to the pCAG-T7 destination vector. For joining two inserts, a 
TAAA overhang has been generated on the 3’ end on the first insert and at the 5’ end on the 
second insert.  
For PCR amplification, the proofreading polymerase Herculase (Agilent) was used and linear 
DNA fragments were purified with the Nucleo Spin and PCR clean-up kit (Machery Nagel).  
The destination vector pCAG-T7 (150 ng) and the PCR amplified inserts were set into a 2:1 
molar ratio and additionally 1xT4 ligase buffer (NEB), T4 ligase (400 U, NEB) and Esp3I 
(10U, Thermo Scientific) was added to the golden gate reaction mix. In a thermocycler, this 
reaction was incubated with the following program: 37 °C/5min, 16 °C/10 min for 10-50 
cycles followed by 5 minutes at 50 °C and 5 minutes at 80 °C to inactivate the ligase.   
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Replication of Plasmid in E.coli and Colony PCR 
For the replication of the plasmid generated by the golden gate reaction, electrocompetent 
E.coli (Top10 Electrocomp, Life Technologies) were transformed using a Micro Pulser 
electroporation apparatus (BioRad Gene Pulser TM) and electroporation cuvettes (1 mm, Bio 
Rad). The electoporator was set to the following conditions (resistance: 200 Ohms, gene 
pulser: 1.5 kV, capacitance: 25 µFD).   
After electroporation, bacteria were immediately placed in Luria-Bertani (LB) medium without 
antibiotics for one hour. Then, transformed E.coli were plated on LB agar containing 100 
μg/ml Ampicillin and for blue-white selection 40 μg/ml 5-bromo-4-chloro-3-indolyl-beta-D-
galactopyranoside (Xgal) and isopropyl beta-D-thiogalactopyranoside (IPTG). Bacteria were 
then cultured over night (8 hours). 
Thirty white colonies have been selected and screened for the correct insert based on PCR 
(“colony PCR”). For this step, a forward primer binding to the pCAGT7 destination vector 
upstream on the insert (CATGCCTTCTTCTTTTTCCTAC) and a reverse primer binding to 
PrP (GGCTTTGGCCGCTTTTTGC) were used. For the Colony PCR the redTaq ready mix 
(Sigma Aldrich) was used and the reactions were incubated in a thermocycler with the 
following touchdown program: 95 °C for 30 seconds, 63 °C with a touch down temperature of 
0.75 °C for 30 seconds and 72 °C for 90 seconds for 20 cycles followed by 95 °C for 30 
seconds, 48 °C for 30 seconds and 72 °C for 90 seconds for 20 cycles. The product was 
then directly loaded on a 2% agar gel and illuminated with UV light. One of the colonies, 
which showed a PCR product with the expected length, was then purified from 7 ml of 
bacterial culture in LB medium using the Nucleo Spin plasmid kit (Machery Nagel) and from 
250 ml culture using the Endotoxin Plasmid Midi kit (Qiagen).  
 
Immunohistochemistry of transfected cells 
The HEK293T cell line was cultured at 37 °C in a humidified atmosphere with 5% CO2. Then 
cells were cultured in a 12-well format on gelatin coated (2% Gelatin) coverslips until they 
reached approximately 90% confluency. Cells were then transfected with the plasmid using 
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Lipofectamine® (1.6 µg DNA, 4% Lipofectamie). One day later, cells were fixed in 4% 
Parafomaldehyde. The cover slips with the fixed cells were then incubated for 10 minutes in 
TritonX solution (0.1% in 0.5% bovine serum albumin dissolved in PBS) and blocked with 
0.5% bovine serum albumin for 45 minutes. Then cells were incubated with POM1 (2 μg ml-1) 
diluted in PBS containing 0.5% bovine serum albumin for 1 hour. After washing, the cells 
were incubated with fluorescent-labeled secondary anti-mouse antibody (1 μg ml-1 Alexa 
Fluor 488). In the last PBS wash 4,6-diamidino-2-phenylindole, dihydrochloride (DAPI; 
Molecular Probes) was added and sections were mounted with Fluor Save (Calbiochem). For 
analysis pictures were taken with a FluoView® FV10i Confocal Laser Scanning System. 
 
Testing of PrP surface expression of transfected cells 
For surface expression analysis cells were cultured in 25T well flasks until they reached 90% 
confluency. Cells were then transfected with the plasmid using Lipofectamine® (8 µg DNA, 
4% Lipofectamie). One day later, the cells were incubated with biotinilytion reagent (1 mg ml-
1, EZ-LinkTM, Thermo Scientific) for 30 minutes at 4 °C, following two washes with 200 mM 
glycine in PBS. After the cells were lysed in RIPA buffer containing protease inhibitor 
(complete mini, Roche), they were passed through a syringe and the protein concentration 
was determined using the bicinchoninic acid assay (Pierce). 50 µl of streptavidin conjugated 
beads (NeutrAvidin Agarose Serin, Thermo Scientific) were then added to 500 ug of protein 
sample and incubated on a rotating wheel at 4 °C overnight to allow binding of the 
biotinilated protein with the streptaviding conjugated beads. The bead protein complexes was 
then washed with 0.1% NP-40 detergent solution by centrifugation (500 g for 2 minutes) five 
times at 4 °C. Then the pulled down proteins were eluted from the beads with loading buffer 
(NuPAGE, Invitrogen) containing 100 mM DTT and boiled at 95 °C for 10 min. The beads 
were removed by centrifugation at maximal speed. 28 µl of eluted protein were the loaded on 
a 12% gel (NuPAGE, Invitrogen) and blotted onto a nitrocellulose membrane. Membranes 
were blocked with 5% w/vol Topblock (Fluka) in Tris-buffered saline supplemented with 
Tween (150 mM NaCl, 10 mM Tris HCl, 0.05% Tween 20 (vol/vol)) and incubated with POM1 
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(100 ng ml-1, Millipore) and mouse anti-actin (100 ng ml-1, Chemicon) in 1% Topblock over 
night. After washing in Tris-buffer, the membrane was incubated with horseradish peroxidase 
(HRP)-conjugated rabbit anti–mouse IgG1 (1:10,000, Zymed) for an hour. Finally, blots were 
developed using SuperSignal West Pico chemiluminescent substrate (Pierce) and visualized 
using the VersaDoc system (model 3000, Bio-Rad). 
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